51 results on '"Kayode, Ogungbenro"'
Search Results
2. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats
- Author
-
Sirisha Tadimalla, Daniel Scotcher, Adam S. Darwich, Steven Sourbron, Kayode Ogungbenro, Gunnar Schütz, Sabina Ziemian, Nicola Melillo, and Aleksandra Galetin
- Subjects
Gadolinium DTPA ,Male ,Physiologically based pharmacokinetic modelling ,Imaging biomarker ,quantitative translation ,physiologically based pharmacokinetic model ,Biological Transport, Active ,Contrast Media ,Organic Anion Transporters ,Pharmaceutical Science ,drug transporters ,Pharmacology ,Article ,Pharmacokinetics ,In vivo ,Drug Discovery ,medicine ,Animals ,imaging biomarker ,Drug Interactions ,drug−drug interactions ,Cells, Cultured ,medicine.diagnostic_test ,Chemistry ,Multidrug resistance-associated protein 2 ,Transporter ,Magnetic resonance imaging ,Magnetic Resonance Imaging ,Rats ,medicine.anatomical_structure ,Liver ,gadoxetate ,Hepatocyte ,Models, Animal ,Hepatocytes ,Molecular Medicine ,hepatobiliary excretion ,Rifampin ,Biomarkers - Abstract
Physiologically based pharmacokinetic (PBPK) models are increasingly used in drug development to simulate changes in both systemic and tissue exposures that arise as a result of changes in enzyme and/or transporter activity. Verification of these model-based simulations of tissue exposure is challenging in the case of transporter-mediated drug–drug interactions (tDDI), in particular as these may lead to differential effects on substrate exposure in plasma and tissues/organs of interest. Gadoxetate, a promising magnetic resonance imaging (MRI) contrast agent, is a substrate of organic-anion-transporting polypeptide 1B1 (OATP1B1) and multidrug resistance-associated protein 2 (MRP2). In this study, we developed a gadoxetate PBPK model and explored the use of liver-imaging data to achieve and refine in vitro–in vivo extrapolation (IVIVE) of gadoxetate hepatic transporter kinetic data. In addition, PBPK modeling was used to investigate gadoxetate hepatic tDDI with rifampicin i.v. 10 mg/kg. In vivo dynamic contrast-enhanced (DCE) MRI data of gadoxetate in rat blood, spleen, and liver were used in this analysis. Gadoxetate in vitro uptake kinetic data were generated in plated rat hepatocytes. Mean (%CV) in vitro hepatocyte uptake unbound Michaelis–Menten constant (Km,u) of gadoxetate was 106 μM (17%) (n = 4 rats), and active saturable uptake accounted for 94% of total uptake into hepatocytes. PBPK–IVIVE of these data (bottom-up approach) captured reasonably systemic exposure, but underestimated the in vivo gadoxetate DCE–MRI profiles and elimination from the liver. Therefore, in vivo rat DCE–MRI liver data were subsequently used to refine gadoxetate transporter kinetic parameters in the PBPK model (top-down approach). Active uptake into the hepatocytes refined by the liver-imaging data was one order of magnitude higher than the one predicted by the IVIVE approach. Finally, the PBPK model was fitted to the gadoxetate DCE–MRI data (blood, spleen, and liver) obtained with and without coadministered rifampicin. Rifampicin was estimated to inhibit active uptake transport of gadoxetate into the liver by 96%. The current analysis highlighted the importance of gadoxetate liver data for PBPK model refinement, which was not feasible when using the blood data alone, as is common in PBPK modeling applications. The results of our study demonstrate the utility of organ-imaging data in evaluating and refining PBPK transporter IVIVE to support the subsequent model use for quantitative evaluation of hepatic tDDI.
- Published
- 2021
3. Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters
- Author
-
Amais Ahmad, Amin Rostami-Hodjegan, Annett Kunze, Frank Jacobs, Jan Snoeys, Kayode Ogungbenro, and Aleksandra Galetin
- Subjects
Male ,Pyridoxic Acid ,Organic anion transporter 1 ,Population ,RM1-950 ,Organic Anion Transporters, Sodium-Independent ,Pharmacology ,Article ,chemistry.chemical_compound ,Pharmacokinetics ,In vivo ,medicine ,Humans ,Computer Simulation ,Drug Interactions ,Pharmacology (medical) ,education ,education.field_of_study ,Cross-Over Studies ,biology ,Probenecid ,Chemistry ,Research ,Homovanillic acid ,Homovanillic Acid ,Articles ,Healthy Volunteers ,Modeling and Simulation ,biology.protein ,Biomarker (medicine) ,Female ,Therapeutics. Pharmacology ,Biomarkers ,medicine.drug - Abstract
Renal clearance of many drugs is mediated by renal organic anion transporters OAT1/3 and inhibition of these transporters may lead to drug‐drug interactions (DDIs). Pyridoxic acid (PDA) and homovanillic acid (HVA) were indicated as potential biomarkers of OAT1/3. The objective of this study was to develop a population pharmacokinetic model for PDA and HVA to support biomarker qualification. Simultaneous fitting of biomarker plasma and urine data in the presence and absence of potent OAT1/3 inhibitor (probenecid, 500 mg every 6 h) was performed. The impact of study design (multiple vs. single dose of OAT1/3 inhibitor) and ability to detect interactions in the presence of weak/moderate OAT1/3 inhibitors was investigated, together with corresponding power calculations. The population models developed successfully described biomarker baseline and PDA/HVA OAT1/3‐mediated interaction data. No prominent effect of circadian rhythm on PDA and HVA individual baseline levels was evident. Renal elimination contributed greater than 80% to total clearance of both endogenous biomarkers investigated. Estimated probenecid unbound in vivo OAT inhibitory constant was up to 6.4‐fold lower than in vitro values obtained with PDA as a probe. The PDA model was successfully verified against independent literature reported datasets. No significant difference in power of DDI detection was found between multiple and single dose study design when using the same total daily dose of 2000 mg probenecid. Model‐based simulations and power calculations confirmed sensitivity and robustness of plasma PDA data to identify weak, moderate, and strong OAT1/3 inhibitors in an adequately powered clinical study to support optimal design of prospective clinical OAT1/3 interaction studies.
- Published
- 2021
4. PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability
- Author
-
Hong Shen, Karelle Ménochet, Yueping Zhang, Hiroyuki Takita, Kayode Ogungbenro, Shelby Barnett, and Aleksandra Galetin
- Subjects
Male ,Coproporphyrins ,Physiologically based pharmacokinetic modelling ,Genotype ,Physiology ,Urine ,Kidney ,Models, Biological ,Sensitivity and Specificity ,Article ,Drug Development ,Pharmacokinetics ,Liver tissue ,Ethnicity ,Humans ,Medicine ,Drug Interactions ,Pharmacology (medical) ,Coproporphyrin I ,Observer Variation ,Sex Characteristics ,biology ,Liver-Specific Organic Anion Transporter 1 ,business.industry ,Research ,lcsh:RM1-950 ,Biological Transport ,Articles ,Healthy Volunteers ,lcsh:Therapeutics. Pharmacology ,Liver ,Modeling and Simulation ,biology.protein ,Biomarker (medicine) ,Female ,SLCO1B1 ,business ,Biomarkers - Abstract
Coproporphyrin I (CPI) is an endogenous biomarker of organic anion transporting polypeptides 1B (OATP1B) activity and associated drug-drug interactions. In this study, a minimal physiologicallybased pharmacokinetic model was developed to investigate the impact of OATP1B1 genotype (c.521T>C), ethnicity, and sex on CPI pharmacokinetics and inter-individual variability in its baseline. The model implemented mechanistic descriptions of CPI hepatic transport between liver blood and liver tissue and renal excretion. Key model parameters (e.g., endogenous CPI synthesis rate, CPI hepatic uptake clearance) were estimated by fitting the model simultaneously to three independent CPI clinical datasets (plasma and urine data) obtained from Caucasian (n=16, male and female) and Asian-Indian (n=26, all male) subjects, with c.521 variants (TT, TC, and CC). The optimized CPI model successfully described the observed data using three covariates (c.521T>C genotype, ethnicity, and sex). Hepatic active uptake of CPI decreased by 75% in 521CC relative to the wild type and by 37% in Asian-Indians relative to Caucasians. CPI synthesis was 24% lower in female relative to male. Parameter sensitivity analysis showed marginal impact of the assumption of CPI synthesis site (blood or liver), resulting in comparable recovery of plasma and urine CPI data. Lower magnitude of CPI-drug interaction was simulated in 521CC subjects, suggesting the risk of under-estimation of CPI-drug interaction without prior OATP1B1 genotyping. The CPI model incorporates key covariates contributing to inter-individual variability in its baseline and highlights the utility of the CPI modelling to facilitate the design of prospective clinical studies to maximise the sensitivity of this biomarker.
- Published
- 2021
5. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug–Drug Interaction Risk in Pediatric Physiologically‐Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study
- Author
-
Jennifer Lang, Ludwig Vincent, Marylore Chenel, Kayode Ogungbenro, and Aleksandra Galetin
- Subjects
Physiologically based pharmacokinetic modelling ,Antifungal Agents ,Cardiotonic Agents ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Metabolite ,Ontogeny ,Pharmacology ,Pediatrics ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacokinetics ,Cytochrome P-450 CYP3A ,Humans ,Medicine ,Drug Interactions ,Ivabradine ,Pharmacology (medical) ,Child ,CYP3A4 ,business.industry ,Infant, Newborn ,Cytochrome P-450 CYP3A Inducers ,Infant ,Ketoconazole ,Liver ,Drug development ,chemistry ,Child, Preschool ,030220 oncology & carcinogenesis ,Pharmacodynamics ,Cytochrome P-450 CYP3A Inhibitors ,business ,medicine.drug - Abstract
Clinical assessment of drug-drug interactions (DDIs) in children is not a common practice in drug development. Therefore, physiologically-based pharmacokinetic (PBPK) modeling can be beneficial for informing drug labeling. Using ivabradine and its metabolite (both cytochrome P450 3A4 enzyme (CYP3A4) substrates), the objectives were (i) to scale ivabradine-metabolite adult PBPK/PD to pediatrics, (ii) to predict the DDIs with a strong CYP3A4 inhibitor, and (iii) to compare the sensitivity of children to DDIs using two CYP3A4 hepatic ontogeny functions: Salem and Upreti. A scaled parent-metabolite PBPK/PD model from adults to children satisfactorily predicted pharmacokinetics (PK) and pharmacodynamics (PD) in 74 children (0.5-18 years) regardless of CYP3A4 hepatic ontogeny function applied. However, using the Salem ontogeny, mean predicted parent and metabolite area under the concentration-time curve over 12 hours (AUC12h ) and heart rate change from baseline were 2-fold, 1.5-fold, and 1.4-fold higher in young children (0.5-3 years old) compared with Upreti ontogeny, respectively. Despite these differences, choice of appropriate hepatic CYP3A4 ontogeny was challenging due to sparse PK and PD data. Different sensitivity to ivabradine-ketoconazole DDIs was simulated in young children relative to adults depending on the choice of hepatic CYP3A4 ontogeny. Predicted ivabradine and metabolite AUCDDI /AUCcontrol were 2-fold lower in the youngest children (0.5-1 year old) compared with adults (Salem function). In contrast, the Upreti function predicted comparable ivabradine DDIs across all age groups, although predicted metabolite AUCDDI/ AUCcontrol was 1.3-fold higher between the youngest children and adults. In the case of PD, differences in predicted DDIs were minor across age groups and between both functions. Current work highlights the importance of careful consideration of hepatic CYP3A4 ontogeny function and implications on labeling recommendations in the pediatric population.
- Published
- 2020
6. Dose individualisation in oncology using chemotherapy‐induced neutropenia: Example of docetaxel in non‐small cell lung cancer patients
- Author
-
Hitesh Mistry, Leon Aarons, Aurélie Lombard, and Kayode Ogungbenro
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Neutropenia ,Antineoplastic Agents ,Docetaxel ,030226 pharmacology & pharmacy ,Metastasis ,Efficacy ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Dosing ,Lung cancer ,Pharmacology ,business.industry ,medicine.disease ,Clinical trial ,Taxoids ,business ,medicine.drug - Abstract
Aims Chemotherapy-induced neutropenia has been associated with an increase in overall survival in non-small cell lung cancer patients. Therefore, neutrophil counts could be an interesting biomarker for drug efficacy as well as linked directly to toxicity. For drugs where neutropenia is dose limiting, neutrophil counts might be used for monitoring drug effect and for dosing optimisation. Methods The relationship between drug effect on the first cycle neutrophil counts and patient survival was explored in a Phase III clinical trial where patients with non-small cell lung cancer were treated with docetaxel. Once the association has been established, dosing optimisation was performed for patients with severe toxicities (neutropenia) without compromising drug efficacy (overall survival). Results After taking into account baseline prognostic factors, such as Eastern Cooperative Oncology Group performance status, smoking status, liver metastasis, tumour burden, neutrophil counts and albumin levels, a model-predicted drug effect on the first cycle neutrophil counts was strongly associated with patient survival (P = .005). Utilising this relationship in a dose optimisation algorithm, 194 out of 366 patients would have benefited from a dose reduction after the first cycle of docetaxel. The simulated 1-year survival probabilities associated with the original dose and the individualised dose were not different. Conclusion The strong relationship between drug effect on the first cycle neutrophil counts and patient survival suggests that this variable could be used to individualise dosing, possibly without needing pharmacokinetic samples. The algorithm highlights that doses could be reduced in case of severe haematological toxicities without compromising drug efficacy.
- Published
- 2020
7. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
- Author
-
Susan M. Abdel-Rahman, Jonathan B. Wagner, Kayode Ogungbenro, Aleksandra Galetin, and J. Steven Leeder
- Subjects
Male ,Simvastatin ,Metabolite ,Pharmacology ,030226 pharmacology & pharmacy ,chemistry.chemical_compound ,0302 clinical medicine ,population pharmacokinetics ,polycyclic compounds ,Metabolites ,Cytochrome P-450 CYP3A ,Pharmacology (medical) ,030212 general & internal medicine ,Population pharmacokinetics ,Child ,metabolites ,education.field_of_study ,biology ,Liver-Specific Organic Anion Transporter 1 ,General Medicine ,children and adolescents ,lipids (amino acids, peptides, and proteins) ,Female ,medicine.drug ,Adult ,Children and adolescents ,Adolescent ,Genotype ,Population ,Hyperlipidemias ,Models, Biological ,Modelling ,modelling ,03 medical and health sciences ,Young Adult ,Pharmacokinetics ,medicine ,Humans ,cardiovascular diseases ,Dosing ,education ,CYP3A5 ,Active metabolite ,business.industry ,organic chemicals ,nutritional and metabolic diseases ,Pharmacokinetics and Disposition ,chemistry ,biology.protein ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,SLCO1B1 ,business - Abstract
Purpose Poor adherence to dietary/behaviour modifications as interventions for hypercholesterolemia in paediatric patients often necessitates the initiation of statin therapy. The aim of this study was to develop a joint population pharmacokinetic model for simvastatin and four metabolites in children and adolescents to investigate sources of variability in simvastatin acid exposure in this patient population, in addition to SLCO1B1 genotype status. Methods Plasma concentrations of simvastatin and its four metabolites, demographic and polymorphism data for OATP1B1 and CYP3A5 were analysed utilising a population pharmacokinetic modelling approach from an existing single oral dose (10 mg C (rs4149056) on the pharmacokinetics of the active metabolite simvastatin acid in children/adolescents, consistent with adult data. In addition, age was identified as a covariate affecting elimination clearances of 6-hydroxymethyl simvastatin acid and 3, 5 dihydrodiol simvastatin metabolites. Conclusion The model developed describes the pharmacokinetics of simvastatin and its metabolites in children/adolescents capturing the effects of both c.521T>C and age on variability in exposure in this patient population. This joint simvastatin metabolite model is envisaged to facilitate optimisation of simvastatin dosing in children/adolescents. Electronic supplementary material The online version of this article (10.1007/s00228-019-02697-y) contains supplementary material, which is available to authorized users.
- Published
- 2019
8. A study of the dosage and duration for levobupivacaine infusion by the caudal‐epidural route in infants aged 3‐6 months
- Author
-
Leon Aarons, Kayode Ogungbenro, Ijeoma Okonkwo, Rita Vashisht, Anju A. Bendon, Adam S. Darwich, Catherine Fullwood, and Davandra Patel
- Subjects
Anesthesia, Epidural ,medicine.drug_class ,caudal-epidural infusion ,levobupivacaine ,Loading dose ,03 medical and health sciences ,0302 clinical medicine ,Racemic bupivacaine ,Pharmacokinetics ,030202 anesthesiology ,030225 pediatrics ,Humans ,Medicine ,Pediatrics, Perinatology, and Child Health ,Prospective Studies ,Anesthetics, Local ,Levobupivacaine ,Pain Measurement ,Pain, Postoperative ,infants ,business.industry ,Local anesthetic ,α -acid glycoprotein ,Bladder Exstrophy ,Infant ,Orosomucoid ,Serum concentration ,Analgesia, Epidural ,Anesthesiology and Pain Medicine ,Anesthesia ,Pediatrics, Perinatology and Child Health ,Caudal epidural ,business ,bladder exstrophy ,pharmacokinetics ,Bladder exstrophy repair ,medicine.drug - Abstract
AimTo investigate total serum levobupivacaine concentrations after a caudal‐epidural loading dose followed by a maintenance infusion in infants aged 3‐6 months over 48 hours.BackgroundThe local anaesthetic, levobupivacaine, is the safer enantiomer of racemic bupivacaine. Present protocols for levobupivacaine are based on studies and pharmacokinetic modelling with racemic bupivacaine. This study will inform clinical practice in this age group and validate the pharmacokinetic model for levobupivacaine infusions in infants, aged 3‐6months.MethodsThe clinical trial was conducted in 8 infants aged 3‐6 months, undergoing bladder exstrophy repair. Pharmacokinetic modelling allowed optimisation of clinical sampling to measure total levobupivacaine and α1‐acid glycoprotein and prediction of the effect of α1‐acid glycoprotein on levobupivacaine plasma protein binding.ResultsThe observed median total levobupivacaine serum concentration was 0.30 mg.L−1 (range: 0.20‐0.70 mg.L−1) at 1 hour after the loading dose of 2 mg.kg−1. The median total levobupivacaine concentration after 47 hours of infusion, at 0.2 mg.h−1.kg−1, was 1.21 mg.L−1 (0.07‐1.85 mg.L−1). Concentrations of α1‐acid glycoprotein were found to rise throughout the study period. Pharmacokinetic modelling suggested that unbound levobupivacaine quickly reached steady state at a concentration of approximately 0.03 mg.L−1.ConclusionThis study examines the pharmacokinetics of levobupivacaine after a loading dose (given over 5 minutes) followed by a maintenance infusion in infants 3‐6 months. The study allows the development of a pharmacokinetic model, combining levobupivacaine and α1‐acid glycoprotein data. Modelling indicates that unbound levobupivacaine quickly reaches steady state once the infusion is started. Simulations suggest that it may be possible to continue the infusion beyond 48 hours.
- Published
- 2018
9. Model-based drug-drug interaction extrapolation strategy from adults to children – risdiplam in pediatric patients with spinal muscular atrophy
- Author
-
Leon Aarons, Heidemarie Kletzl, Yumi Cleary, Michael Gertz, Andreas Günther, Katja Heinig, Aleksandra Galetin, Kayode Ogungbenro, and Paul Grimsey
- Subjects
Adult ,Male ,Oncology ,Physiologically based pharmacokinetic modelling ,medicine.medical_specialty ,Adolescent ,CYP3A ,Midazolam ,Models, Biological ,Muscular Atrophy, Spinal ,Young Adult ,Pharmacokinetics ,In vivo ,Internal medicine ,Humans ,Medicine ,Drug Interactions ,Pharmacology (medical) ,Child ,Pharmacology ,business.industry ,Infant, Newborn ,Area under the curve ,Infant ,Spinal muscular atrophy ,SMA ,medicine.disease ,Pyrimidines ,Neuromuscular Agents ,Child, Preschool ,Cytochrome P-450 CYP3A Inhibitors ,Female ,business ,Azo Compounds ,medicine.drug - Abstract
Risdiplam (Evrysdi) improves motor neuron function in patients with spinal muscular atrophy (SMA) and has been approved for the treatment of patients ≥2 months old. Risdiplam exhibits time-dependent inhibition of cytochrome P450 (CYP) 3A in vitro. While many pediatric patients receive risdiplam, a drug-drug interaction (DDI) study in pediatric patients with SMA was not feasible. Therefore, a novel physiologically-based pharmacokinetic (PBPK) model-based strategy was proposed to extrapolate DDI risk from healthy adults to children with SMA in an iterative manner. A clinical DDI study was performed in healthy adults at relevant risdiplam exposures observed in children. Risdiplam caused an 1.11-fold increase in the ratio of midazolam area under the curve with and without risdiplam (AUCR)), suggesting an 18-fold lower in vivo CYP3A inactivation constant compared with the in vitro value. A pediatric PBPK model for risdiplam was validated with independent data and combined with a validated midazolam pediatric PBPK model to extrapolate DDI from adults to pediatric patients with SMA. The impact of selected intestinal and hepatic CYP3A ontogenies on the DDI susceptibility in children relative to adults was investigated. The PBPK analysis suggests that primary CYP3A inhibition by risdiplam occurs in the intestine rather than the liver. The PBPK-predicted risdiplam CYP3A inhibition risk in pediatric patients with SMA aged 2 months-18 years was negligible (midazolam AUCR of 1.09-1.18) and included in the US prescribing information of risdiplam. Comprehensive evaluation of the sensitivity of predicted CYP3A DDI on selected intestinal and hepatic CYP3A ontogeny functions, together with PBPK model-based strategy proposed here, aim to guide and facilitate DDI extrapolations in pediatric populations.
- Published
- 2021
10. Anakinra in COVID-19: important considerations for clinical trials
- Author
-
David Brough, Cathal John Hannan, Stuart M. Allan, Claire O'Leary, Omar N. Pathmanaban, Andy Vail, James Galea, Kayode Ogungbenro, Andrew T. King, Megan Wright, Sharon Hulme, and Hiren C. Patel
- Subjects
medicine.medical_specialty ,Anakinra ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,MEDLINE ,Article ,Clinical trial ,Rheumatology ,medicine ,Immunology and Allergy ,Intensive care medicine ,business ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
11. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method
- Author
-
Ludwig Vincent, Kayode Ogungbenro, Marylore Chenel, Jennifer Lang, and Aleksandra Galetin
- Subjects
Adult ,Male ,Physiologically based pharmacokinetic modelling ,Metabolite ,Cmax ,Pharmaceutical Science ,Administration, Oral ,Pharmacology ,030226 pharmacology & pharmacy ,Models, Biological ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacokinetics ,Oral administration ,Heart Rate ,medicine ,Cytochrome P-450 CYP3A ,Humans ,Computer Simulation ,Drug Interactions ,Ivabradine ,Tissue Distribution ,Bayes Theorem ,Cardiovascular Agents ,Healthy Volunteers ,Fruit and Vegetable Juices ,Enterocytes ,Ketoconazole ,chemistry ,Intestinal Absorption ,030220 oncology & carcinogenesis ,Pharmacodynamics ,Area Under Curve ,Cytochrome P-450 CYP3A Inhibitors ,Administration, Intravenous ,Female ,medicine.drug - Abstract
Ivabradine and its metabolite both demonstrate heart rate–reducing effect (If current inhibitors) and undergo CYP3A4 metabolism. The purpose of this study was to develop a joint parent-metabolite physiologically based pharmacokinetic (PBPK)/pharmacodynamic (PD) model to predict the PK and PD of ivabradine and its metabolite following intravenous (i.v.) or oral administration (alone or co-administered with CYP3A4 inhibitors). Firstly, a parent-metabolite disposition model was developed and optimised using individual plasma concentration-time data following i.v. administration of ivabradine or metabolite within a Bayesian framework. Secondly, the model was extended and combined with a mechanistic intestinal model to account for oral absorption and drug-drug interactions (DDIs) with CYP3A4 inhibitors (ketoconazole, grapefruit juice). Lastly, a PD model was linked to the PBPK model to relate parent and metabolite PK to heart rate (HR) reduction. The disposition model described successfully parent-metabolite PK following i.v. administration. Following integration of a gut model, the PBPK model adequately predicted plasma concentration profiles and the DDI risk (92% and 85% of predicted AUC+inhibitor/AUCcontrol and Cmax+inhibitor/Cmaxcontrol for ivabradine and metabolite within the prediction limits). Ivabradine-metabolite PBPK model was linked to PD by using the simulated unbound parent-metabolite concentrations in the heart. This approach successfully predicted the effects of both entities on HR (observed vs predicted − 7.7/− 5.9 bpm and − 15.8/− 14.0 bpm, control and ketoconazole group, respectively). This study provides a framework for PBPK/PD modelling of a parent-metabolite and can be scaled to other populations or used for investigation of untested scenarios (e.g. evaluation of DDI risk in special populations).
- Published
- 2020
12. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
- Author
-
Aristides Dokoumetzidis, Kosmas Sarafidis, Kayode Ogungbenro, H G Gika, Eleni Agakidou, Aggeliki Kontou, A Tsiligiannis, Olga Begou, and Emmanuel Roilides
- Subjects
Male ,medicine.medical_specialty ,Staphylococcus ,Population ,Urology ,Renal function ,Gestational Age ,Microbial Sensitivity Tests ,Loading dose ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Sepsis ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,education ,Pharmacology ,Volume of distribution ,0303 health sciences ,education.field_of_study ,030306 microbiology ,Maintenance dose ,business.industry ,Infant, Newborn ,Liter ,Staphylococcal Infections ,Anti-Bacterial Agents ,Infectious Diseases ,Pharmacodynamics ,Premature Birth ,Female ,Teicoplanin ,business ,Monte Carlo Method - Abstract
Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the currently recommended dosing regimen in term and preterm neonates. By using an optimal design approach, a prospective PK study was designed and implemented in 60 neonates with postmenstrual ages (PMA) of 26 to 43 weeks. A loading dose of 16 mg/kg was administered at day 1, followed by a maintenance dose of 8 mg/kg daily. Plasma concentrations were quantified by high-pressure liquid chromatography–mass spectrometry. Population PK (popPK) analysis was performed using NONMEM software. Monte-Carlo (MC) simulations were performed to evaluate currently recommended dosing based on a pharmacodynamic index of area under the concentration-time curve (AUC)/MIC ratio of ≥400. A two-compartment model with linear elimination best described the data by the following equations: clearance (CL) = 0.0227 × (weight [wt]/1,765)(0.75) × (estimated creatinine clearance [eCRCL]/22)(0.672), central compartment volume of distribution (V1) = 0.283 (wt/1,765), intercompartmental clearance (Q) = 0.151 (wt/1,765)(0.75), and peripheral compartment volume (V2) = 0.541 (wt/1,765). The interindividual variability estimates for CL, V1, and V2 were 36.5%, 45.7%, and 51.4%, respectively. Current weight (wt) and estimated creatinine clearance (eCRCL) significantly explained the observed variability. MC simulation demonstrated that, with the current dosing regimen, an AUC/MIC ratio of ≥400 was reached by only 68.5% of neonates with wt of
- Published
- 2020
13. Does 'Birth' as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine Bias
- Author
-
Amin Rostami-Hodjegan, Kayode Ogungbenro, Trevor N. Johnson, Arran B. J. Hodgkinson, and Farzaneh Salem
- Subjects
Renal function ,Physiology ,Contrast Media ,Gestational Age ,urologic and male genital diseases ,Kidney Function Tests ,030226 pharmacology & pharmacy ,Models, Biological ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,birth ,Organometallic Compounds ,Medicine ,Humans ,Pharmacology (medical) ,Child ,Full Term ,Pharmacology ,Inulin Clearance ,Creatinine ,glomerular filtration rate ,urogenital system ,business.industry ,maturation ,Body Weight ,Postmenstrual Age ,Age Factors ,Infant, Newborn ,Inulin ,Gestational age ,Infant ,Pediatric Pharmacology ,Anthropometry ,neonates ,Anti-Bacterial Agents ,Postnatal age ,chemistry ,030220 oncology & carcinogenesis ,Child, Preschool ,Premature Birth ,business - Abstract
Glomerular filtration rate (GFR) is an important measure of renal function. Various models for its maturation have recently been compared; however, these have used markers, which are subject to different renal elimination processes. Inulin clearance data (a purer probe of GFR) collected from the literature were used to determine age‐related changes in GFR aspects of renal drug excretion in pediatrics. An ontogeny model was derived using a best‐fit model with various combinations of covariates such as postnatal age, gestational age at birth, and body weight. The model was applied to the prediction of systemic clearance of amikacin, gentamicin, vancomycin, and gadobutrol. During neonatal life, GFR increased as a function of both gestational age at birth and postnatal age, hence implying an impact of birth and a discrepancy in GFR for neonates with the same postmenstrual age depending on gestational age at birth (ie, neonates who were outside the womb longer had higher GFR, on average). The difference in GFR between pre‐term and full‐term neonates with the same postmenstrual age was negligible from beyond 1.25 years. Considering both postnatal age and gestational age at birth in GFR ontogeny models is important because postmenstrual age alone ignores the impact of birth. Most GFR models use covariates of body size in addition to age. Therefore, prediction from these models will also depend on the change in anthropometric characteristics with age. The latter may not be similar in various ethnic groups, and this makes the head‐to‐head comparison of models very challenging.
- Published
- 2020
14. Impact of tumour size measurement inter‑operator variability on model‑based drug effect evaluation
- Author
-
Hitesh Mistry, Ivelina Gueoguieva, Aurélie Lombard, Leon Aarons, Kayode Ogungbenro, and Sonya C. Chapman
- Subjects
Cancer Research ,Lung Neoplasms ,Antineoplastic Agents ,Toxicology ,Inter-operator variability ,Modelling ,Efficacy ,Correlation ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Statistics ,Linear regression ,Covariate ,Humans ,Multicenter Studies as Topic ,Medicine ,Pharmacology (medical) ,Time point ,Response Evaluation Criteria in Solid Tumors ,Drug effect ,Observer Variation ,Pharmacology ,Models, Statistical ,Drug effect evaluation ,business.industry ,Tumor Burden ,Clinical trial ,Clinical Trials, Phase III as Topic ,Oncology ,Tumour size ,030220 oncology & carcinogenesis ,Original Article ,Tumour size measurements ,business - Abstract
Purpose During oncology clinical trials, tumour size (TS) measurements are commonly used to monitor disease progression and to assess drug efficacy. We explored inter-operator variability within a subset of a phase III clinical trial conducted from August 1995 to February 1997 and its impact on drug effect evaluation using a tumour growth inhibition model. Methods One hundred twenty lesions were measured twice at each time point; once at the hospital and once at the centralised centre. A visual analysis was performed to identify trends within the profiles over time. Linear regression and relative error ratios were used to explore the inter-operator variability of raw TS measurements and model-based estimates. Results While correlation between patient-level estimates of drug effect was poor (r2 = 0.28), variability between the study-level estimates was much less affected (9%). Conclusions The global evaluation of drug effect using modelling approaches might not be affected by inter-operator variability. However, the exploration of covariates for drug effect and the characterisation of an exposure–tumour shrinkage relationship seems limited by the high measurement variability that translates to a poor correlation of individual drug effect estimates. This might be addressed by the use of more precise computer-aided measurement methods.
- Published
- 2020
15. Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers
- Author
-
Keith A. Rodvold, William W. Hope, Kayode Ogungbenro, Emmanuel Boselli, and Timothy Felton
- Subjects
Adult ,Male ,Serum ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,medicine.drug_class ,Critical Illness ,030106 microbiology ,Population ,Antibiotics ,Young Adult ,03 medical and health sciences ,Pharmacokinetics ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Dosing ,Young adult ,education ,Lung ,Piperacillin ,Pharmacology ,education.field_of_study ,business.industry ,Middle Aged ,respiratory system ,Healthy Volunteers ,Anti-Bacterial Agents ,Infectious Diseases ,medicine.anatomical_structure ,Pharmacodynamics ,Female ,business ,medicine.drug - Abstract
BackgroundSevere infections of the respiratory tracts of critically ill patients are common and associated with excess morbidity and mortality. Piperacillin is commonly used to treat pulmonary infections in critically ill patients. Adequate antibiotic concentration in the epithelial lining fluid (ELF) of the lung is essential for successful treatment of pulmonary infection.ObjectivesTo compare piperacillin pharmacokinetics/pharmacodynamics in the serum and ELF of healthy volunteers and critically ill patients.MethodsPiperacillin concentrations in the serum and ELF of healthy volunteers and critically ill patients were compared using population methodologies.ResultsMedian piperacillin exposure was significantly higher in the serum and the ELF of critically ill patients compared with healthy volunteers. The IQR for serum piperacillin exposure in critically ill patients was six times greater than for healthy volunteers. The IQR for piperacillin exposure in the ELF of critically ill patients was four times greater than for healthy volunteers. The median pulmonary piperacillin penetration ratio was 0.31 in healthy volunteers and 0.54 in critically ill patients.ConclusionsGreater variability in serum and ELF piperacillin concentrations is observed in critically ill patients compared with healthy adult subjects and must be considered in the development of dosage regimens. Pulmonary penetration of antimicrobial agents should be studied in critically ill patients, as well as healthy volunteers, during drug development to ensure appropriate dosing of patients with pneumonia.
- Published
- 2018
16. Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs
- Author
-
Adam S. Darwich, Kayode Ogungbenro, Amin Rostami-Hodjegan, and Oliver Hatley
- Subjects
Cancer Research ,Individualized dosing ,business.industry ,Pharmacokinetic modeling ,modeling ,Population pharmacokinetics ,Pharmacology ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,physiologically-based pharmacokinetics ,individualized dosing ,Oncology ,030220 oncology & carcinogenesis ,oncology ,Medicine ,Radiology, Nuclear Medicine and imaging ,Dosing ,business - Abstract
The prospect of precision dosing in oncology is attractive for several reasons. Many anticancer drugs display narrow therapeutic indices, where suboptimal therapy may lead to severe patient outcomes. Clinical study participant recruitment is seldom extended beyond the intended patient population, leading to difficulties in patient recruitment in dedicated clinical trials. The high rate of non-responders and high cost of cancer therapy warrant novel solutions to increase clinical effectiveness and cost-benefit, pharmacokinetic (PK) modeling and model-informed precision dosing (MIPD) can help to maximize these. PK modeling provides a quantitative framework to account for inter-individual variability in drug exposure, the influence of covariates and extrapolation to special populations or drug-drug interactions, using physiologically-based PK (PBPK) modeling. Here we present the current state of PK modeling in precision dosing of anticancer drugs and illustrate its utility, based on an extensive literature review and numerous case examples from both pharmaceutical industry and healthcare focused research. While some great progress has been made in implementing model-informed dosage guidance in the drug label and much research has been carried out to address clinically relevant dosing questions, the uptake of MIPD has been modest in healthcare. The success of PK modeling in industry has been made possible through collaborative efforts between regulators, industry and academia. Collaboration between academia, healthcare and industry, and financial support for research into patient benefit, cost-benefit and clinical effectiveness of these approaches is imperative for wider adaption of PK modeling in precision dosing of anticancer drugs
- Published
- 2017
17. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions
- Author
-
Marylore Chenel, Ludwig Vincent, Jennifer Lang, Aleksandra Galetin, and Kayode Ogungbenro
- Subjects
Digoxin ,Physiologically based pharmacokinetic modelling ,business.industry ,Pharmaceutical Science ,Prodrug ,Pharmacology ,Models, Biological ,Dabigatran ,Therapeutic index ,Pharmaceutical Preparations ,MicroDose ,Pharmacokinetics ,medicine ,Humans ,Distribution (pharmacology) ,Drug Interactions ,Prospective Studies ,Dosing ,business ,medicine.drug - Abstract
Background Dabigatran etexilate (DABE) has been suggested as a clinical probe for intestinal P-glycoprotein (P-gp)-mediated drug-drug interaction (DDI) studies and, as an alternative to digoxin. Clinical DDI data with various P-gp inhibitors demonstrated a dose-dependent inhibition of P-gp with DABE. The aims of this study were to develop a joint DABE (prodrug)-dabigatran reduced physiologically-based-pharmacokinetic (PBPK) model and to evaluate its ability to predict differences in P-gp DDI magnitude between a microdose and a therapeutic dose of DABE. Methods A joint DABE-dabigatran PBPK model was developed with a mechanistic intestinal model accounting for the regional P-gp distribution in the gastrointestinal tract. Model input parameters were estimated using DABE and dabigatran pharmacokinetic (PK) clinical data obtained after administration of DABE alone or with a strong P-gp inhibitor, itraconazole, and over a wide range of DABE doses (from 375 µg to 400 mg). Subsequently, the model was used to predict extent of DDI with additional P-gp inhibitors and with different DABE doses. Results The reduced DABE-dabigatran PBPK model successfully described plasma concentrations of both prodrug and metabolite following administration of DABE at different dose levels and when co-administered with itraconazole. The model was able to capture the dose dependency in P-gp mediated DDI. Predicted magnitude of itraconazole P-gp DDI was higher at the microdose (predicted vs. observed median fold-increase in AUC+inh/AUCcontrol (min-max) = 5.88 (4.29–7.93) vs. 6.92 (4.96–9.66) ) compared to the therapeutic dose (predicted median fold-increase in AUC+inh/AUCcontrol = 3.48 (2.37–4.84) ). In addition, the reduced DABE-dabigatran PBPK model predicted successfully the extent of DDI with verapamil and clarithromycin as P-gp inhibitors. Model-based simulations of dose staggering predicted the maximum inhibition of P-gp when DABE microdose was concomitantly administered with itraconazole solution; simulations also highlighted dosing intervals required to minimise the DDI risk depending on the DABE dose administered (microdose vs. therapeutic). Conclusions This study provides a modelling framework for the evaluation of P-gp inhibitory potential of new molecular entities using DABE as a clinical probe. Simulations of dose staggering and regional differences in the extent of intestinal P-gp inhibition for DABE microdose and therapeutic dose provide model-based guidance for design of prospective clinical P-gp DDI studies.
- Published
- 2021
18. Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)
- Author
-
Nicholas H. G. Holford, Joseph F. Standing, Flora T. Musuamba, Norbert Benda, Andrew C. Hooker, Solange Corriol-Rohou, Frank Bretz, P H van der Graaf, Falk Ehmann, Martin Posch, I. Skottheim Rusten, S. Y. A. Cheung, Bjoern Bornkamp, Lena E. Friberg, Kristin E. Karlsson, James W.T. Yates, Robert Hemmings, A. Brochot, Efthymios Manolis, Neal Thomas, Susan Cole, Shampa Das, F. Serone, Valeria Gigante, Scott Berry, Thomas Dumortier, Justin L. Hay, and Kayode Ogungbenro
- Subjects
Research design ,Operations research ,business.industry ,Management science ,MEDLINE ,030226 pharmacology & pharmacy ,01 natural sciences ,Pharmacometrics ,3. Good health ,Clinical trial ,010104 statistics & probability ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Drug development ,Modeling and Simulation ,Medicine ,Pharmacology (medical) ,Pairwise comparison ,0101 mathematics ,business ,Systems pharmacology - Abstract
Inadequate dose selection for confirmatory trials is currently still one of the most challenging issues in drug development, as illustrated by high rates of late-stage attritions in clinical development and postmarketing commitments required by regulatory institutions. In an effort to shift the current paradigm in dose and regimen selection and highlight the availability and usefulness of well-established and regulatory-acceptable methods, the European Medicines Agency (EMA) in collaboration with the European Federation of Pharmaceutical Industries Association (EFPIA) hosted a multistakeholder workshop on dose finding (London 4-5 December 2014). Some methodologies that could constitute a toolkit for drug developers and regulators were presented. These methods are described in the present report: they include five advanced methods for data analysis (empirical regression models, pharmacometrics models, quantitative systems pharmacology models, MCP-Mod, and model averaging) and three methods for study design optimization (Fisher information matrix (FIM)-based methods, clinical trial simulations, and adaptive studies). Pairwise comparisons were also discussed during the workshop; however, mostly for historical reasons. This paper discusses the added value and limitations of these methods as well as challenges for their implementation. Some applications in different therapeutic areas are also summarized, in line with the discussions at the workshop. There was agreement at the workshop on the fact that selection of dose for phase III is an estimation problem and should not be addressed via hypothesis testing. Dose selection for phase III trials should be informed by well-designed dose-finding studies; however, the specific choice of method(s) will depend on several aspects and it is not possible to recommend a generalized decision tree. There are many valuable methods available, the methods are not mutually exclusive, and they should be used in conjunction to ensure a scientifically rigorous understanding of the dosing rationale.
- Published
- 2017
19. Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance
- Author
-
R. A. Bolarinwa, Kayode Ogungbenro, Oluseye O. Bolaji, Babatunde Ayodeji Adeagbo, Muheez A. Durosinmi, and T. A. Olugbade
- Subjects
Adult ,Male ,Adolescent ,Population ,Black People ,Nigeria ,Antineoplastic Agents ,Pharmacology ,Models, Biological ,030226 pharmacology & pharmacy ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Humans ,Medicine ,Pharmacology (medical) ,education ,Volume of distribution ,education.field_of_study ,Dose-Response Relationship, Drug ,business.industry ,Area under the curve ,Reproducibility of Results ,Myeloid leukemia ,Imatinib ,Middle Aged ,NONMEM ,Bioavailability ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,Female ,business ,medicine.drug - Abstract
Imatinib, a tyrosine kinase inhibitor, is the drug of choice for the treatment of chronic myeloid leukemia in Nigeria. Several studies have established interindividual and interpopulation variations in imatinib disposition although no pharmacokinetic study have been conducted in an African population since the introduction of the drug. This study explored a population pharmacokinetic approach to investigate the disposition of imatinib in Nigerians and examined the involvement of some covariates including genetic factors in the variability of the drug disposition with a view to optimize the use of the drug in this population. A total of 250 plasma concentrations from 126 chronic myeloid leukemia patients were quantified using a validated method. A population pharmacokinetic model was fitted to the data using NONMEM VII software, and the influences of 12 covariates were investigated. The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 ± 1.8 L/h., 12.05 ± 2.1 hours, 23.26 ± 0.6 μg·h/mL, and 299 ± 20.4 L, respectively. Whole blood count, ethnicity, CYP3A5*3, and ABCB1 C3435T were found to have significant influence on the apparent clearance, while the interindividual variability in clearance and interoccasion variability in bioavailability were 17.4% and 20.4%, respectively. There was a wide variability in apparent clearance and area under the curve compared to those reported in other populations. Thus, treatment with a standard dose of imatinib in this population may not produce the desired effect in most of the patients, whereas continuous exposure to a low drug concentration could lead to pharmacokinetic-derived resistance. The authors suggest the need for therapeutic drug monitoring-guided dose individualization in this population.
- Published
- 2017
20. Development and validation of a methotrexate adherence assay
- Author
-
Isabel Riba-Garcia, Anne Barton, Suzanne M M Verstappen, James Bluett, Kayode Ogungbenro, Richard D. Unwin, and Thierry Wendling
- Subjects
Male ,Oncology ,musculoskeletal diseases ,rheumatoid arthritis ,medicine.medical_specialty ,Dose ,Immunology ,030204 cardiovascular system & hematology ,Mass Spectrometry ,General Biochemistry, Genetics and Molecular Biology ,Medication Adherence ,Model validation ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Pharmacokinetics ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,adherence ,pharmacokinetic ,Chromatography, High Pressure Liquid ,Directly Observed Therapy ,Aged ,030203 arthritis & rheumatology ,Biological therapies ,Dose-Response Relationship, Drug ,business.industry ,Reproducibility of Results ,Drug administration ,Middle Aged ,assay ,medicine.disease ,3. Good health ,Methotrexate ,Antirheumatic Agents ,Rheumatoid arthritis ,Female ,business ,medicine.drug - Abstract
BackgroundThe first-line therapy for rheumatoid arthritis (RA) is weekly oral methotrexate (MTX) at low dosages (7.5–25 mg/week). However, ~40% of patients are non-adherent which may explain why some do not respond and need to start more expensive biological therapies. To monitor adherence more accurately and develop strategies to improve it, a validated objective MTX adherence test is required.ObjectiveTo develop and validate the diagnostic accuracy of a novel MTX adherence assay using high-performance liquid chromatography–selected reaction monitoring– mass spectrometry (HPLC-SRM-MS) based biochemical analysis of drug levels.Methods20 patients with RA underwent MTX pharmacokinetic assessment using HPLC-SRM-MS MTX plasma concentration analysis over a 6-day period. Directly observed therapy was the reference standard. Pharmacokinetic model validation was performed using independent plasma samples from real-world patients (n=50) with self-reported times of drug administration. Following assay optimisation, the sensitivity of the assay to detect adherence was established using samples from an observational cohort study (n=138).ResultsA two-compartment pharmacokinetic model was developed and validated. Simulations described the sensitivity required for MTX detection over 7 days; subsequent assay optimisation and retesting of samples confirmed that all patients were correctly identified as MTX adherers. Using real-world samples, the assays sensitivity was 95%.ConclusionNon-adherence to MTX is common and can have a significant effect on disease activity. HPLC-SRM-MS plasma analysis accurately detects MTX adherence. The validated objective test could easily be used in clinic to identify patients requiring adherence support.
- Published
- 2019
21. Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared to rosuvastatin and coproporphyrin I
- Author
-
Karelle Ménochet, Aleksandra Galetin, Griffith W Humphreys, Hong Shen, Shelby Barnett, and Kayode Ogungbenro
- Subjects
Male ,0301 basic medicine ,Coproporphyrins ,medicine.drug_class ,Glycocholic acid ,Pharmacology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Humans ,Rosuvastatin ,Rosuvastatin Calcium ,chemistry.chemical_classification ,biology ,Bile acid ,Liver-Specific Organic Anion Transporter 1 ,Area under the curve ,Fatty acid ,Organic anion-transporting polypeptide ,030104 developmental biology ,chemistry ,Glycodeoxycholic acid ,biology.protein ,Molecular Medicine ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Taurodeoxycholic acid ,Biomarkers ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Endogenous biomarkers can be clinically relevant tools for the assessment of transporter function in vivo and corresponding drug-drug interactions (DDIs). The aim of this study was to perform systematic evaluation of plasma data obtained for 20 endogenous molecules in the same healthy subjects (n = 8-12) in the absence and presence of organic anion transporting polypeptide (OATP) inhibitor rifampicin (600 mg, single dose). The extent of rifampicin DDI magnitude [the ratio of the plasma concentration-time area under the curve (AUCR)], estimated fraction transported (fT), and baseline variability was compared across the biomarkers and relative to rosuvastatin and coproporphyrin I (CPI). Out of the 20 biomarkers investigated tetradecanedioate (TDA), hexadecanedioate (HDA), glycocholic acid, glycodeoxycholic acid (GDCA), taurodeoxycholic acid (TDCA), and coproporphyrin III (CPIII) showed the high AUCR (2.1-8.5) and fT (0.5-0.76) values, indicative of substantial OATP1B-mediated transport. A significant positive correlation was observed between the individual GDCA and TDCA AUCRs and the magnitude of rosuvastatin-rifampicin interaction. The CPI and CPIII AUCRs were significantly correlated, but no clear trend was established with the rosuvastatin AUCR. Moderate interindividual variability (15%-62%) in baseline exposure and AUCR was observed for TDA, HDA, and CPIII. In contrast, bile acids demonstrated high interindividual variability (69%-113%) and significant decreases in baseline plasma concentrations during the first 4 hours. This comprehensive analysis in the same individuals confirms that none of the biomarkers supersede CPI in the evaluation of OATP1B-mediated DDI risk. Monitoring of CPI and GDCA/TDCA may be beneficial for dual OATP1B/sodium-taurocholate cotransporting polypeptide inhibitors with consideration of challenges associated with large inter- and intraindividual variability observed for bile acids. Benefit of monitoring combined biomarkers (CPI, one bile acid and one fatty acid) needs to be confirmed with larger data sets and against multiple OATP1B clinical probes and perpetrators.
- Published
- 2019
22. Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
- Author
-
Kayode Ogungbenro, Hitesh Mistry, Leon Aarons, and Thierry Wendling
- Subjects
0301 basic medicine ,Oncology ,Antimetabolites, Antineoplastic ,Cancer Research ,medicine.medical_specialty ,Toxicology ,Deoxycytidine ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Pancreatic cancer ,Tumour size time-series ,Metastatic pancreatic cancer ,Humans ,Medicine ,Pharmacology (medical) ,Hierarchical modelling ,Survival analysis ,Proportional Hazards Models ,Retrospective Studies ,Pharmacology ,business.industry ,Proportional hazards model ,Retrospective cohort study ,Models, Theoretical ,Prognosis ,medicine.disease ,Gemcitabine ,Tumor Burden ,Pancreatic Neoplasms ,030104 developmental biology ,Clinical Trials, Phase III as Topic ,chemistry ,Tumour size ,030220 oncology & carcinogenesis ,Original Article ,business ,medicine.drug - Abstract
Purpose Measures derived from longitudinal tumour size data have been increasingly utilised to predict survival of patients with solid tumours. The aim of this study was to examine the prognostic value of such measures for patients with metastatic pancreatic cancer undergoing gemcitabine therapy. Methods The control data from two Phase III studies were retrospectively used to develop (271 patients) and validate (398 patients) survival models. Firstly, 31 baseline variables were screened from the training set using penalised Cox regression. Secondly, tumour shrinkage metrics were interpolated for each patient by hierarchical modelling of the tumour size time-series. Subsequently, survival models were built by applying two approaches: the first aimed at incorporating model-derived tumour size metrics in a parametric model, and the second simply aimed at identifying empirical factors using Cox regression. Finally, the performance of the models in predicting patient survival was evaluated on the validation set. Results Depending on the modelling approach applied, albumin, body surface area, neutrophil, baseline tumour size and tumour shrinkage measures were identified as potential prognostic factors. The distributional assumption on survival times appeared to affect the identification of risk factors but not the ability to describe the training data. The two survival modelling approaches performed similarly in predicting the validation data. Conclusions A parametric model that incorporates model-derived tumour shrinkage metrics in addition to other baseline variables could predict reasonably well survival of patients with metastatic pancreatic cancer. However, the predictive performance was not significantly better than a simple Cox model that incorporates only baseline characteristics. Electronic supplementary material The online version of this article (doi:10.1007/s00280-016-2994-x) contains supplementary material, which is available to authorized users.
- Published
- 2016
23. Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
- Author
-
Cathal John Hannan, Sharon Hulme, Stuart M. Allan, Claire O'Leary, Andy Vail, David Brough, Luisa Bernardinelli, Hiren C. Patel, Kayode Ogungbenro, James Galea, Carlo Berzuini, Omar N. Pathmanaban, Megan Wright, and Andrew T. King
- Subjects
Male ,Neutrophils ,statistics & research methods ,Cohort Studies ,Leukocyte Count ,Research Methods ,Urea ,Aged, 80 and over ,General Medicine ,Middle Aged ,Prognosis ,Hospitalization ,C-Reactive Protein ,Area Under Curve ,Creatinine ,Medicine ,Biomarker (medicine) ,Female ,Coronavirus Infections ,intensive & critical care ,medicine.medical_specialty ,Pneumonia, Viral ,Risk Assessment ,Betacoronavirus ,respiratory infections ,Covariate ,medicine ,Humans ,Lymphocyte Count ,Baseline (configuration management) ,Pandemics ,Partial correlation ,Aged ,Retrospective Studies ,Receiver operating characteristic ,SARS-CoV-2 ,business.industry ,COVID-19 ,Bilirubin ,Retrospective cohort study ,United Kingdom ,Exploratory data analysis ,ROC Curve ,Emergency medicine ,business ,Biomarkers ,Predictive modelling - Abstract
ObjectivesBeing able to predict which patients with COVID-19 are going to deteriorate is important to help identify patients for clinical and research practice. Clinical prediction models play a critical role in this process, but current models are of limited value because they are typically restricted to baseline predictors and do not always use contemporary statistical methods. We sought to explore the benefits of incorporating dynamic changes in routinely measured biomarkers, non-linear effects and applying ‘state-of-the-art’ statistical methods in the development of a prognostic model to predict death in hospitalised patients with COVID-19.DesignThe data were analysed from admissions with COVID-19 to three hospital sites. Exploratory data analysis included a graphical approach to partial correlations. Dynamic biomarkers were considered up to 5 days following admission rather than depending solely on baseline or single time-point data. Marked departures from linear effects of covariates were identified by employing smoothing splines within a generalised additive modelling framework.Setting3 secondary and tertiary level centres in Greater Manchester, the UK.Participants392 hospitalised patients with a diagnosis of COVID-19.Results392 patients with a COVID-19 diagnosis were identified. Area under the receiver operating characteristic curve increased from 0.73 using admission data alone to 0.75 when also considering results of baseline blood samples and to 0.83 when considering dynamic values of routinely collected markers. There was clear non-linearity in the association of age with patient outcome.ConclusionsThis study shows that clinical prediction models to predict death in hospitalised patients with COVID-19 can be improved by taking into account both non-linear effects in covariates such as age and dynamic changes in values of biomarkers.
- Published
- 2020
24. An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysis
- Author
-
James Clark, Kayode Ogungbenro, Mark P Saunders, Alkesh Patel, and Robert Duncombe
- Subjects
Oncology ,medicine.medical_specialty ,Body Surface Area ,Population ,Pharmaceutical Science ,Cetuximab ,Vial ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Pharmacokinetics ,Internal medicine ,cetuximab ,medicine ,Animals ,Humans ,cetuximab dose ,030212 general & internal medicine ,Dosing ,education ,Pharmacology ,Body surface area ,0303 health sciences ,education.field_of_study ,Manchester Cancer Research Centre ,030306 microbiology ,business.industry ,ResearchInstitutes_Networks_Beacons/mcrc ,Regimen ,monoclonal antibody ,Cost analysis ,Costs and Cost Analysis ,dose banding ,business ,medicine.drug - Abstract
Objectives Cetuximab dosing is based on body surface area (BSA), an approach that is associated with significant wastage due to available vial sizes. NHS England recently introduced an alternative strategy for cetuximab dosing based on dose banding. The aim of this work was to investigate approaches to cetuximab dosing to improve its cost-effectiveness. Methods A simulation study using a population pharmacokinetic model was used to assess the performance of dosing strategies using exposure, probability of target attainment and cost. Two dosage regimens (500 and 400/250 mg/m2) were investigated; 5% and 10% dose banding, fixed and optimised dosing strategies were evaluated and compared to BSA strategy. Key findings The percentage of the total cost associated with wastage for the 400/250 mg/m2 regimen were 8.75%, 5.13%, 3.61%, 9.2% and 0% for BSA; 5 and 10% bands; fixed and optimal strategies, respectively. Similar results were obtained for 500 mg/m2 regimen. In comparison with BSA strategy, other strategies have comparable or improved performance. Optimised strategy showed consistent performance and ensures equal exposure and probability of target attainment. Conclusions Cost-effectiveness of cetuximab treatment can be improved with alternative strategies by reducing wastage without compromising exposure.
- Published
- 2018
25. Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist
- Author
-
Nancy J. Rothwell, Stephen J. Hopkins, Sharon Hulme, Kayode Ogungbenro, Pippa J. Tyrrell, and James Galea
- Subjects
medicine.drug_class ,Population ,Phases of clinical research ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Pharmacokinetics ,Humans ,Medicine ,Computer Simulation ,Infusions, Intravenous ,education ,Cerebrospinal Fluid ,Pharmacology ,education.field_of_study ,Models, Statistical ,business.industry ,Antagonist ,Subarachnoid Hemorrhage ,Dose-ranging study ,Receptor antagonist ,Interleukin 1 Receptor Antagonist Protein ,Blood ,Interleukin 1 receptor antagonist ,Research Design ,030220 oncology & carcinogenesis ,Anesthesia ,business ,Algorithms ,030217 neurology & neurosurgery - Abstract
Interleukin-1 receptor antagonist, a naturally-occurring antagonist to the pro-inflammatory cytokine Interleukin-1, is already in clinical use. In experimental models of stroke, Interleukin-1 receptor antagonist in cerebrospinal fluid has been associated with cerebral neuroprotection and in a phase I clinical trial in patients with subarachnoid haemorrhage it crosses the blood-cerebrospinal fluid barrier. The aims of the current work were to design a dose-ranging clinical study in patients and to analyse the plasma and cerebrospinal fluid data obtained using a population pharmacokinetic modelling approach. The study was designed using prior information: a published population pharmacokinetic model and associated parameter estimates. Simulations were carried out to identify combinations of intravenous bolus and 4 h infusion doses that could achieve a concentration of 100 ng/ml in cerebrospinal fluid within approximately 30 min. The most informative time points for plasma and cerebrospinal fluid were obtained prospectively; optimisation identified five sampling time points that were included in the 15 time points in the present study design. All plasma and cerebrospinal fluid concentration data from previous and current studies were combined for updated analysis. The result of the simulations showed that a dosage regimen of 500 mg intravenous bolus and 10 mg/kg/h could achieve the target concentration, however four other regimens that represent a stepwise increase in maximum concentration were also selected. Analysis of the updated data showed improvement in parameter accuracy and predictive performance of the model; the percentage relative standard errors for fixed and random-effects parameters were
- Published
- 2015
26. Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics
- Author
-
Leon Aarons, Kayode Ogungbenro, Thierry Wendling, and Swati Dumitras
- Subjects
Adult ,Male ,Indoles ,Bayesian probability ,Population ,Administration, Oral ,Population pharmacokinetics ,Pharmacology ,Models, Biological ,Drug Administration Schedule ,chemistry.chemical_compound ,Pharmacokinetics ,Oral administration ,Humans ,Medicine ,Mavoglurant ,Computer Simulation ,Drug Interactions ,Tissue Distribution ,Child ,education ,Clinical Trials as Topic ,education.field_of_study ,Models, Statistical ,business.industry ,Continuous flow ,Age Factors ,Brain ,Bayes Theorem ,Markov Chains ,Ketoconazole ,chemistry ,Child, Preschool ,Administration, Intravenous ,Female ,business ,Excitatory Amino Acid Antagonists ,Monte Carlo Method ,medicine.drug - Abstract
Mavoglurant (MVG) is an antagonist at the metabotropic glutamate receptor-5 currently under clinical development at Novartis Pharma AG for the treatment of central nervous system diseases. The aim of this study was to develop and optimise a population whole-body physiologically-based pharmacokinetic (WBPBPK) model for MVG, to predict the impact of drug-drug interaction (DDI) and age on its pharmacokinetics. In a first step, the model was fitted to intravenous (IV) data from a clinical study in adults using a Bayesian approach. In a second step, the optimised model was used together with a mechanistic absorption model for exploratory Monte Carlo simulations. The ability of the model to predict MVG pharmacokinetics when orally co-administered with ketoconazole in adults or administered alone in 3-11 year-old children was evaluated using data from three other clinical studies. The population model provided a good description of both the median trend and variability in MVG plasma pharmacokinetics following IV administration in adults. The Bayesian approach offered a continuous flow of information from pre-clinical to clinical studies. Prediction of the DDI with ketoconazole was consistent with the results of a non-compartmental analysis of the clinical data (threefold increase in systemic exposure). Scaling of the WBPBPK model allowed reasonable extrapolation of MVG pharmacokinetics from adults to children. The model can be used to predict plasma and brain (target site) concentration-time profiles following oral administration of various immediate-release formulations of MVG alone or when co-administered with other drugs, in adults as well as in children.
- Published
- 2015
27. Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity
- Author
-
Kayode Ogungbenro and Leon Aarons
- Subjects
Pharmacology ,Drug ,Physiologically based pharmacokinetic modelling ,Thiopurine methyltransferase ,media_common.quotation_subject ,Biology ,Red blood cell ,medicine.anatomical_structure ,Pharmacokinetics ,Toxicity ,medicine ,biology.protein ,Pharmacology (medical) ,Dosing ,Intracellular ,media_common - Abstract
AIMS: To extend the physiologically based pharmacokinetic (PBPK) model developed for 6-mercaptopurine to account for intracellular metabolism and to explore the role of genetic polymorphism in the TPMT enzyme on the pharmacokinetics of 6-mercaptopurine. METHODS: The developed PBPK model was extended for 6-mercaptopurine to account for intracellular metabolism and genetic polymorphism in TPMT activity. System and drug specific parameters were obtained from the literature or estimated using plasma or intracellular red blood cell concentrations of 6-mercaptopurine and its metabolites. Age-dependent changes in parameters were implemented for scaling, and variability was also introduced for simulation. The model was validated using published data. RESULTS: The model was extended successfully. Parameter estimation and model predictions were satisfactory. Prediction of intracellular red blood cell concentrations of 6-thioguanine nucleotide for different TPMT phenotypes (in a clinical study that compared conventional and individualized dosing) showed results that were consistent with observed values and reported incidence of haematopoietic toxicity. Following conventional dosing, the predicted mean concentrations for homozygous and heterozygous variants, respectively, were about 10 times and two times the levels for wild-type. However, following individualized dosing, the mean concentration was around the same level for the three phenotypes despite different doses. CONCLUSIONS: The developed PBPK model has been extended for 6-mercaptopurine and can be used to predict plasma 6-mercaptopurine and tissue concentration of 6-mercaptopurine, 6-thioguanine nucleotide and 6-methylmercaptopurine ribonucleotide in adults and children. Predictions of reported data from clinical studies showed satisfactory results. The model may help to improve 6-mercaptopurine dosing, achieve better clinical outcome and reduce toxicity.
- Published
- 2015
28. Dose rationalisation of pembrolizumab and nivolumab using pharmacokinetic modelling and simulation and cost analysis
- Author
-
Richard Nuttall, Alkesh Patel, James Clark, Robert Duncombe, Kayode Ogungbenro, and Paul Lorigan
- Subjects
Pharmacokinetic modeling ,Programmed Cell Death 1 Receptor ,Antineoplastic Agents ,Pembrolizumab ,Pharmacology ,Antibodies, Monoclonal, Humanized ,030226 pharmacology & pharmacy ,Fixed dose ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Medicine ,Humans ,Pharmacology (medical) ,Drug Dosage Calculations ,Dosing ,Dose Optimisation ,business.industry ,Nivolumab ,030220 oncology & carcinogenesis ,Drug Design ,Monoclonal ,Cost analysis ,Costs and Cost Analysis ,business ,Dose Banding ,Simulation - Abstract
Pembrolizumab and nivolumab are highly selective anti-programmed cell death 1 (PD-1) antibodies approved for the treatment of advanced malignancies. Variable exposure and significant wastage have been associated with body size dosing of monoclonal antibodies (mAbs). The following dosing strategies were evaluated using simulations: body weight, dose banding, fixed dose, and pharmacokinetic (PK)-based methods. The relative cost to body weight dosing for band, fixed 150 mg and 200 mg, and PK-derived strategies were -15%, -25%, + 7%, and -16% for pembrolizumab and -8%, -6%, and -10% for band, fixed, and PK-derived strategies for nivolumab, respectively. Relative to mg/kg doses, the median exposures were -1.0%, -4.6%, + 27.1%, and +3.0% for band, fixed 150 mg, fixed 200 mg, and PK-derived strategies, respectively, for pembrolizumab and -3.1%, + 1.9%, and +1.4% for band, fixed 240 mg, and PK-derived strategies, respectively, for nivolumab. Significant wastage can be reduced by alternative dosing strategies without compromising exposure and efficacy.
- Published
- 2017
29. Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study
- Author
-
Sharon Hulme, Andy Vail, Hiren C. Patel, Karen J. Illingworth, Nikolaos Tzerakis, Kayode Ogungbenro, James Galea, Andrew T. King, Pippa J. Tyrrell, Stephen J. Hopkins, Margaret E. Hoadley, Catherine McMahon, Sylvia Scarth, and Nancy J. Rothwell
- Subjects
0301 basic medicine ,Adult ,Male ,Subarachnoid hemorrhage ,Injections, Subcutaneous ,Ischemia ,Glasgow Outcome Scale ,Inflammation ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,medicine ,Humans ,Single-Blind Method ,Aged ,Anakinra ,biology ,business.industry ,C-reactive protein ,Area under the curve ,Fibrinogen ,Receptors, Interleukin-1 ,General Medicine ,Middle Aged ,Subarachnoid Hemorrhage ,medicine.disease ,Clinical trial ,Interleukin 1 Receptor Antagonist Protein ,030104 developmental biology ,Interleukin 1 receptor antagonist ,C-Reactive Protein ,Treatment Outcome ,Anesthesia ,biology.protein ,Female ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Biomarkers ,medicine.drug - Abstract
OBJECTIVEAneurysmal subarachnoid hemorrhage (aSAH) is a devastating cerebrovascular event with long-term morbidity and mortality. Patients who survive the initial bleeding are likely to suffer further early brain injury arising from a plethora of pathological processes. These may result in a worsening of outcome or death in approximately 25% of patients and may contribute to longer-term cognitive dysfunction in survivors. Inflammation, mediated by the cytokine interleukin-1 (IL-1), is an important contributor to cerebral ischemia after diverse forms of brain injury, including aSAH. Its effects are attenuated by its naturally occurring antagonist, IL-1 receptor antagonist (IL-1Ra [anakinra]). The authors hypothesized that administration of additional subcutaneous IL-1Ra would reduce inflammation and associated plasma markers associated with poor outcome following aSAH.METHODSThis was a randomized, open-label, single-blinded study of 100 mg subcutaneous IL-1Ra, administered twice daily in patients with aSAH, starting within 3 days of ictus and continuing until 21 days postictus or discharge from the neurosurgical center, whichever was earlier. Blood samples were taken at admission (baseline) and at Days 3–8, 14, and 21 postictus for measurement of inflammatory markers. The primary outcome was difference in plasma IL-6 measured as area under the curve between Days 3 and 8, corrected for baseline value. Secondary outcome measures included similar area under the curve analyses for other inflammatory markers, plasma pharmacokinetics for IL-1Ra, and clinical outcome at 6 months.RESULTSInterleukin-1Ra significantly reduced levels of IL-6 and C-reactive protein (p < 0.001). Fibrinogen levels were also reduced in the active arm of the study (p < 0.002). Subcutaneous IL-1Ra was safe, well tolerated, and had a predictable plasma pharmacokinetic profile. Although the study was not powered to investigate clinical effect, scores of the Glasgow Outcome Scale–extended at 6 months were better in the active group; however, this outcome did not reach statistical significance.CONCLUSIONSSubcutaneous IL-1Ra is safe and well tolerated in aSAH. It is effective in reducing peripheral inflammation. These data support a Phase III study investigating the effect of IL-1Ra on outcome following aSAH.Clinical trial registration no.: EudraCT: 2011-001855-35 (www.clinicaltrialsregister.eu)
- Published
- 2017
30. Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identification
- Author
-
Kayode Ogungbenro, Emma C. Martin, James W.T. Yates, and Leon Aarons
- Subjects
Blood Glucose ,medicine.medical_treatment ,Fisher information matrix ,Pharmaceutical Science ,030209 endocrinology & metabolism ,01 natural sciences ,Models, Biological ,Minimal model ,Correlation ,010104 statistics & probability ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Double-Blind Method ,Diabetes mellitus ,Statistics ,Parameter estimation ,medicine ,Diabetes Mellitus ,Insulin ,Humans ,0101 mathematics ,Fisher information ,Mathematics ,Pharmacology ,Cross-Over Studies ,Estimation theory ,Glucose Tolerance Test ,medicine.disease ,minimal model ,Glucose ,Clamp ,symbols ,Administration, Intravenous ,Intravenous Glucose Tolerance Test ,Insulin Resistance - Abstract
Objective The minimal model is used to estimate insulin sensitivity in patients with diabetes, following an intravenous glucose tolerance test (IVGTT). Issues have been reported regarding parameter estimation, including correlation between insulin sensitivity and action parameters. The objective was to reduce these issues, by modifying the input of glucose in the test. Methods Data were available for 24 volunteers following an IVGTT and glucose clamp test. Correlation between parameters was explored using likelihood heatmaps. An integrated glucose–insulin model was used to simulate glucose and insulin concentrations following new glucose inputs. The improved input for the test was selected by finding the minimum inverse of the determinant of the Fisher information matrix. Key findings When the minimal model was fitted to the IVGTT data, there was clear correlation between the insulin parameters. With the glucose clamp, all parameters were correlated and badly estimated. The modified input, a bolus dose followed by constant infusion, resulted in improvement in parameter estimation and reduction in parameter correlation. Conclusions It is possible to reduce the issues with parameter estimation in the minimal model by modifying the glucose input, leading to a simplified test deign and a reduction in the total amount of glucose infused.
- Published
- 2017
31. Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
- Author
-
SN de Wildt, Lawrence J. Lesko, J Boiani, J. S. Leeder, Niloufar Marsousi, Amin Rostami-Hodjegan, Alexander A. Vinks, Athena F. Zuppa, Adam S. Darwich, Kayode Ogungbenro, Michael Neely, Leon Aarons, Paolo Vicini, Youssef Daali, TN Johnson, C. A. J. Knibbe, Jeannine S. McCune, J. R. Powell, James M. Cook, J-L Reny, D Fairman, and Pediatric Surgery
- Subjects
medicine.medical_specialty ,Special populations ,Cost-Benefit Analysis ,Alternative medicine ,MEDLINE ,Precision Medicine/trends ,Pharmacology ,030226 pharmacology & pharmacy ,Models, Biological ,03 medical and health sciences ,0302 clinical medicine ,Models ,Integrated ,Health care ,medicine ,Humans ,Pharmacology (medical) ,Dosing ,Precision Medicine ,Polypharmacy ,ddc:615 ,Pharmaceutical Preparations/administration & dosage ,Cost–benefit analysis ,ddc:617 ,business.industry ,Delivery of Health Care, Integrated ,Biological ,Clinical reality ,Risk analysis (engineering) ,Pharmaceutical Preparations ,030220 oncology & carcinogenesis ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,business ,Delivery of Health Care ,Forecasting - Abstract
Item does not contain fulltext Patient groups prone to polypharmacy and special subpopulations are susceptible to suboptimal treatment. Refined dosing in special populations is imperative to improve therapeutic response and/or lowering the risk of toxicity. Model-informed precision dosing (MIPD) may improve treatment outcomes by achieving the optimal dose for an individual patient. There is, however, relatively little published evidence of large-scale utility and impact of MIPD, where it is often implemented as local collaborative efforts between academia and healthcare. This article highlights some successful applications of bringing MIPD to clinical care and proposes strategies for wider integration in healthcare. Considerations are brought up herein that will need addressing to see MIPD become "widespread clinical practice," among those, wider interdisciplinary collaborations and the necessity for further evidence-based efficacy and cost-benefit analysis of MIPD in healthcare. The implications of MIPD on regulatory policies and pharmaceutical development are also discussed as part of the roadmap.
- Published
- 2017
32. A physiologically based pharmacokinetic model for Valproic acid in adults and children
- Author
-
Kayode, Ogungbenro, Leon, Aarons, and Rima, Nabbout
- Subjects
Adult ,Valproic Acid ,Physiologically based pharmacokinetic modelling ,Adolescent ,business.industry ,Pharmaceutical Science ,Pharmacology ,medicine.disease ,Models, Biological ,Young Adult ,Route of administration ,Pharmacokinetics ,Dravet syndrome ,In vivo ,Stiripentol ,Humans ,Medicine ,Distribution (pharmacology) ,Tissue Distribution ,business ,medicine.drug - Abstract
Valproic acid is an anti-convulscant drug that is widely used in the treatment of different types of epilepsy and since its introduction the clinical use has increased rapidly both as a sole agent and in combination therapies. The mechanism of action has been linked to blockade of voltage-dependent sodium channels and potentiation of GABAergic transmission. The most widely used route of administration of Valproic acid is oral, although it can also be given intravenously and rectally and its pharmacokinetics has been studied extensively. The aim of this work was to develop a physiologically based pharmacokinetic model for plasma and tissue/organ prediction in children and adults following intravenous and oral dosing of Valproic acid. The plasma/tissue concentration profile will be used for clinical trial simulation in Dravet syndrome, a rare form of epilepsy in children where the combination of Valproic acid, stiripentol and clobazam has shown remarkable results. A physiologically based pharmacokinetic model was developed with compartments for gut lumen, enterocyte, gut tissue, systemic blood, kidney, liver, brain, spleen, muscle and rest of body. System and drug specific parameters for the model were obtained from the literature from in vitro and in vivo experiments. The model was initially developed for adults and scaled to children using age-dependent changes in anatomical and physiological parameters and ontogeny functions for enzyme maturation assuming the same elimination pathways in adults and children. The results from the model validation showed satisfactory prediction of plasma concentration both in terms of mean prediction and variability in children and adults following intravenous and oral dosing especially after single doses. The model also adequately predicts clearance in children. Due to limited distribution of Valproic acid into tissues, the concentration in plasma is about 8-9 times higher than tissues/organs. The model could help to improve clinical outcome in the treatment of Dravet syndrome through dose optimisation.
- Published
- 2014
33. A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children
- Author
-
Kayode Ogungbenro, Catherine CHIRON, and Renzo Guerrini
- Subjects
Pharmacology ,Volume of distribution ,Physiologically based pharmacokinetic modelling ,Clobazam ,Chemistry ,Organic Chemistry ,Pharmaceutical Science ,medicine.disease ,Confidence interval ,Pharmacokinetics ,Dravet syndrome ,medicine ,Stiripentol ,Molecular Medicine ,Pharmacology (medical) ,Active metabolite ,Biotechnology ,medicine.drug - Abstract
To develop a physiologically based pharmacokinetic model in adults and children for clobazam, its active metabolite norclobazam and stiripentol and to account for significant clinical interaction that has been reported when clobazam and stiripentol are co-administered. A PBPK model with ten compartments was developed. An in vitro-in vivo extrapolation technique was used to scale clearance in children for clobazam and norclobazam and clearance parameters for stiripentol were obtained from fitting. Other drug and system parameters were obtained from the literature. The tissue/blood partition coefficients adequately predict observed volume of distribution for clobazam and stiripentol. In a clinical study in children where clobazam was administered alone and co-administered with stiripentol, the predicted and observed minimum concentration at steady state (mean and 95% confidence interval) during clobazam monotherapy were 0.19 (0.05–0.49 mg/L) and 0.20 (0.17–0.23 mg/L), respectively, and predicted and observed norclobazam concentrations were 0.49 (0.16–1.38 mg/L) and 0.95 (0.91–0.99 mg/L), respectively. From an interaction study with stiripentol the predicted stiripentol concentration was 10.12 (2.51–39.36 mg/L) and the observed concentration was 10.0 (8.3–11.7 mg/L); the predicted clobazam concentration was 0.29 (0.07–1.05 mg/L) and the observed concentration was 0.31 (0.24–0.38 mg/L); and the predicted norclobazam concentration was 2.30 (0.45–5.53 mg/L) and the observed concentration was 4.32 (3.77–4.87 mg/L). The PBPK model adequately described observed data and the extent of interaction between clobazam/norclobazam and stiripentol.
- Published
- 2014
34. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate
- Author
-
Kayode, Ogungbenro, Leon, Aarons, and Rima, Nabbout
- Subjects
Antimetabolites, Antineoplastic ,Physiologically based pharmacokinetic modelling ,Adolescent ,Administration, Oral ,Pharmacology ,Models, Biological ,Young Adult ,chemistry.chemical_compound ,Pharmacokinetics ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Computer Simulation ,Drug Interactions ,Tissue Distribution ,Child ,Xanthine oxidase ,Mercaptopurine ,business.industry ,Infant, Newborn ,Infant ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Methotrexate ,medicine.anatomical_structure ,chemistry ,Child, Preschool ,Toxicity ,Administration, Intravenous ,Bone marrow ,business ,Drug metabolism ,medicine.drug - Abstract
6-mercaptopurine (6-MP) is a purine antimetabolite and prodrug that undergoes extensive intracellular metabolism to produce thionucleotides, active metabolites which have cytotoxic and immunosuppressive properties. Combination therapies involving 6-MP and methotrexate have shown remarkable results in the cure of childhood acute lymphoblastic leukaemia (ALL) in the last 30 years. 6-MP undergoes very extensive intestinal and hepatic metabolism following oral dosing due to the activity of xanthine oxidase leading to very low and highly variable bioavailability and methotrexate has been demonstrated as an inhibitor of xanthine oxidase. Despite the success recorded in the use of 6-MP in ALL, there is still lack of effect and life threatening toxicity in some patients due to variability in the pharmacokinetics of 6-MP. Also, dose adjustment during treatment is still based on toxicity. The aim of the current work was to develop a mechanistic model that can be used to simulate trial outcomes and help to improve dose individualisation and dosage regimen optimisation. A physiological based pharmacokinetic model was proposed for 6-MP, this model has compartments for stomach, gut lumen, enterocyte, gut tissue, spleen, liver vascular, liver tissue, kidney vascular, kidney tissue, skin, bone marrow, thymus, muscle, rest of body and red blood cells. The model was based on the assumption of the same elimination pathways in adults and children. Parameters of the model include physiological parameters and drug-specific parameter which were obtained from the literature or estimated using plasma and red blood cell concentration data. Age-dependent changes in parameters were implemented for scaling and variability was also introduced on the parameters for prediction. Inhibition of 6-MP first-pass effect by methotrexate was implemented to predict observed clinical interaction between the two drugs. The model was developed successfully and plasma and red blood cell concentrations were adequately predicted both in terms of mean prediction and variability. The predicted interaction between 6-MP and methotrexate was slightly lower than the reported clinical interaction between the two drugs. The model can be used to predict plasma and tissue concentration in adults and children following oral and intravenous dosing and may ultimately help to improve treatment outcome in childhood ALL patients.
- Published
- 2014
35. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate
- Author
-
Kayode, Ogungbenro, Leon, Aarons, and Polina, Kurbatova
- Subjects
Antimetabolites, Antineoplastic ,Physiologically based pharmacokinetic modelling ,Adolescent ,medicine.drug_class ,Administration, Oral ,Pharmacology ,Models, Biological ,Antimetabolite ,Young Adult ,Pharmacokinetics ,Reference Values ,medicine ,Humans ,Distribution (pharmacology) ,Computer Simulation ,Tissue Distribution ,Child ,Kidney ,medicine.diagnostic_test ,business.industry ,Infant, Newborn ,Infant ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Mercaptopurine ,Methotrexate ,medicine.anatomical_structure ,Therapeutic drug monitoring ,Child, Preschool ,Administration, Intravenous ,business ,medicine.drug - Abstract
Methotrexate is an antimetabolite and antifolate drug that is widely used in the treatment of malignancies and auto-immune disorders. In childhood acute lymphoblastic leukaemia, methotrexate is often combined with 6-mercaptopurine and both of them have been shown to be very effective for maintenance of remission. Large variability in the pharmacokinetics of methotrexate has led to increasing use of therapeutic drug monitoring in its clinical use to identify patients with high risk of toxicity and optimise clinical outcome. A physiologically based pharmacokinetic model was developed for methotrexate for oral and intravenous dosing and adults and paediatric use. The model has compartments for stomach, gut lumen, enterocyte, gut tissue, spleen, liver vascular, liver tissue, gall bladder, systemic plasma, red blood cells, kidney vascular, kidney tissue, skin, bone marrow, thymus, muscle and rest of body. A mechanistic model was also developed for the kidney to account for renal clearance of methotrexate via filtration and secretion. Variability on system and drug specific parameters was incorporated in the model to reflect observed clinical data and assuming the same pathways in adults and children, age-dependent changes in body size, organ volumes and plasma flows, the model was scaled to children. The model was developed successfully for adults and parameters such as net secretion clearance, biliary transit time and red blood cell distribution and binding parameters were estimated from published adult profiles. A relationship between fraction absorbed and dose using reported mean bioavailability data in the literature was also established. The model also incorporates non-linear binding in some tissues that has been described in the literature. Predictions using this model provide adequate description of observed plasma concentration data in adults and children. The model can be used to predict plasma and tissue concentrations of methotrexate following intravenous and oral dosing in adults and children and therefore help to improve clinical outcome.
- Published
- 2014
36. Reduced parent-metabolite(s) physiologically-based pharmacokinetic model: Application to mycophenolic acid
- Author
-
Kayode Ogungbenro, Adam S. Darwich, Aleksandra Galetin, and Norikazu Matsunaga
- Subjects
Pharmacology ,chemistry.chemical_compound ,Chromatography ,chemistry ,Pharmacokinetics ,Model application ,Metabolite ,medicine ,Pharmaceutical Science ,Pharmacology (medical) ,Mycophenolic acid ,medicine.drug - Published
- 2019
37. Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: Which measure of variability should be used?
- Author
-
Leon Aarons, Trevor N. Johnson, Pavan Vajjah, Farzaneh Salem, Amin Rostami-Hodjegan, and Kayode Ogungbenro
- Subjects
Adult ,Male ,Physiologically based pharmacokinetic modelling ,Biomedical Research ,Midazolam ,Extrapolation ,Ibuprofen ,Clinical pharmacokinetic ,Models, Biological ,Theophylline ,Age groups ,Pharmacokinetics ,Caffeine ,Statistics ,Humans ,Medicine ,Pharmacology (medical) ,Child ,Pharmacology ,Measure (data warehouse) ,business.industry ,Infant, Newborn ,Infant ,Infant newborn ,Sample size determination ,Area Under Curve ,Child, Preschool ,Sample Size ,Female ,Itraconazole ,business - Abstract
A new approach for calculation of sample size in pediatric clinical pharmacokinetic studies was suggested based on desired precision for a pharmacokinetic parameter of interest. The estimate of variability for sample size calculations could be obtained from different sources. It is not known whether these sources constantly show higher/lower variability across compounds and age groups. We obtained estimates of variability for clearance, volume of distribution and area under the plasma concentration-time curve for 5 drugs from adult/pediatric classic clinical pharmacokinetic studies, and physiologically based pharmacokinetics (PBPK) combined with in vitro-in vivo extrapolation. Estimates were applied to the proposal methodology for non-compartmental analysis. Sample size was different for each drug based on various estimates of variability from different pharmacokinetic parameters and depending on the age. Overall, there was no consistent discrepancy in sample size calculated according to the source of variability. A conservative approach should be taken when using "precision based methodology" knowing that various sources of initial estimates of variability will not lead to similar sample size calculations. Although PBPK simulations could be used for estimating variability, further work is required to investigate the best approach to estimate variability of pharmacokinetic parameters in pediatric populations and hence sample size calculations.
- Published
- 2013
38. Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction
- Author
-
Jaclyn A. Smith, Huda Badri, Kayode Ogungbenro, Imran Satia, Timothy Felton, Kimberley Holt, Nikolaos Tsamandouras, Paul M. O'Byrne, Stephen J. Fowler, and Mark Woodhead
- Subjects
pharmacodynamic modeling ,Adult ,Male ,medicine.medical_specialty ,Immunology ,transient receptor potential vanilloid type 1 ,Bronchi ,Respiratory physiology ,vagus ,Gastroenterology ,Bronchial Provocation Tests ,Atopy ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,Interquartile range ,Internal medicine ,Administration, Inhalation ,medicine ,Journal Article ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Asthma ,2. Zero hunger ,Neurons ,Dose-Response Relationship, Drug ,business.industry ,respiratory system ,Middle Aged ,medicine.disease ,3. Good health ,respiratory tract diseases ,030228 respiratory system ,chemistry ,Cough ,Bronchial hyperresponsiveness ,Capsaicin ,Anesthesia ,Exhaled nitric oxide ,Female ,business ,Body mass index - Abstract
Background Cough in asthmatic patients is a common and troublesome symptom. It is generally assumed coughing occurs as a consequence of bronchial hyperresponsiveness and inflammation, but the possibility that airway nerves are dysfunctional has not been fully explored. Objectives We sought to investigate capsaicin-evoked cough responses in a group of patients with well-characterized mild-to-moderate asthma compared with healthy volunteers and assess the influences of sex, atopy, lung physiology, inflammation, and asthma control on these responses. Methods Capsaicin inhalational challenge was performed, and cough responses were analyzed by using nonlinear mixed-effects modeling to estimate the maximum cough response evoked by any concentration of capsaicin (E max ) and the capsaicin dose inducing half-maximal response (ED 50 ). Results Ninety-seven patients with stable asthma (median age, 23 years [interquartile range, 21-27 years]; 60% female) and 47 healthy volunteers (median age, 38 years [interquartile range, 29-47 years]; 64% female) were recruited. Asthmatic patients had higher E max and lower ED 50 values than healthy volunteers. E max values were 27% higher in female subjects ( P = .006) and 46% higher in patients with nonatopic asthma ( P = .003) compared with healthy volunteers. Also, patients with atopic asthma had a 21% lower E max value than nonatopic asthmatic patients ( P = .04). The ED 50 value was 65% lower in female patients ( P = .0001) and 71% lower in all asthmatic patients ( P = .0008). ED 50 values were also influenced by asthma control and serum IgE levels, whereas E max values were related to 24-hour cough frequency. Age, body mass index, FEV 1 , PC 20 , fraction of exhaled nitric oxide, blood eosinophil counts, and inhaled steroid treatment did not influence cough parameters. Conclusion Patients with stable asthma exhibited exaggerated capsaicin-evoked cough responses consistent with neuronal dysfunction. Nonatopic asthmatic patients had the highest cough responses, suggesting this mechanism might be most important in type 2–low asthma phenotypes.
- Published
- 2016
39. A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: An evaluation using simulation
- Author
-
Leon Aarons and Kayode Ogungbenro
- Subjects
Absorption (pharmacology) ,medicine.medical_specialty ,Direct assessment ,Pharmaceutical Science ,Models, Biological ,Gastroenterology ,Pharmacokinetics ,Internal medicine ,medicine ,Humans ,Computer Simulation ,Identifiability analysis ,Intestinal Mucosa ,Radionuclide Imaging ,Breath test ,Carbon Isotopes ,Chromatography ,Gastric emptying ,medicine.diagnostic_test ,Chemistry ,Stomach ,digestive, oral, and skin physiology ,Kinetics ,medicine.anatomical_structure ,Breath Tests ,Gastric Emptying ,Caprylates ,Algorithms - Abstract
The aim of this paper is to assess the performance of a new mechanistic model for analysing 13C-octanoic acid breath test data using simulation studies. The 13C-octanoic acid breath test is widely used for indirect assessment of the rate of gastric emptying and it is yet to achieve universal acceptance due to inconsistencies when the results are compared with simultaneous and direct measurements using scintigraphy. The new semi-mechanistic model has five separate compartments; stomach, intestine, central and peripheral body and breath compartments. Stomach and breath profiles were simulated for 50 individuals under four conditions: variability on all parameters; no variability on the rate constant of gastric emptying and the rate constant of absorption; variability on the rate constant of gastric emptying and the rate constant of absorption only; and no variability on all parameters. A mono-exponential model was fitted to the stomach profile and the new semi-mechanistic model and three other widely used methods were fitted to the breath profiles. The gastric emptying half times from stomach profiles correlate better (R2 = 1, 1, 1, 1 for the four conditions) with the half emptying times from the semi-mechanistic model compared with half emptying times from the modified exponential model (R2 = 0.72, 0.53, 0.88, 1), Ghoos method (R2 = 0.72, 0.54, 0.88, 1) and Wagner–Nelson method (R2 = 0.79, 0.68, 0.89, 1) for the four simulation studies. The semi-mechanistic model is very effective for the assessment of GE using the 13C-octanoic acid breath test and could be applied in the development of drugs that influence GE.
- Published
- 2012
40. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors
- Author
-
Ann K. Daly, B. Kevin Park, Farhad Kamali, Sameh Al-Zubiedi, Leon Aarons, Ivan Matthews, Andrea L. Jorgensen, Steven Lane, Ellen Hatch, Kayode Ogungbenro, Munir Pirmohamed, Panos Deloukas, and Dyfrig A. Hughes
- Subjects
Pharmacology ,Volume of distribution ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Warfarin ,CYP2C19 ,Confidence interval ,NONMEM ,Internal medicine ,Medicine ,Pharmacology (medical) ,business ,education ,CYP2C9 ,Pharmacogenetics ,medicine.drug - Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • A number of pharmacokinetic studies have focused on S-warfarin. These have shown that demographic factors, such as bodyweight, genetic factors, such as CYP2C9 genotype, and interacting medicines, particularly amiodarone, contribute to the interindividual estimates of clearance. WHAT THIS STUDY ADDS • This study not only reinforces what has previously been learned about S-warfarin, but also provides an insight into the pharmacokinetics of R-warfarin. The study also focuses on individuals who are on long-term warfarin therapy, which is more reflective of clinical practice. BACKGROUND Warfarin is a drug with a narrow therapeutic index and large interindividual variability in daily dosing requirements. Patients commencing warfarin treatment are at risk of bleeding due to excessive anticoagulation caused by overdosing. The interindividual variability in dose requirements is influenced by a number of factors, including polymorphisms in genes mediating warfarin pharmacology, co-medication, age, sex, body size and diet. AIMS To develop population pharmacokinetic models of both R- and S-warfarin using clinical and genetic factors and to identify the covariates which influence the interindividual variability in the pharmacokinetic parameters of clearance and volume of distribution in patients on long-term warfarin therapy. METHODS Patients commencing warfarin therapy were followed up for 26 weeks. Plasma warfarin enantiomer concentrations were determined in 306 patients for S-warfarin and in 309 patients for R-warfarin at 1, 8 and 26 weeks. Patients were also genotyped for CYP2C9 variants (CYP2C9*1,*2 and *3), two single-nucleotide polymorphisms (SNPs) in CYP1A2, one SNP in CYP3A4 and six SNPs in CYP2C19. A base pharmacokinetic model was developed using NONMEM software to determine the warfarin clearance and volume of distribution. The model was extended to include covariates that influenced the between-subject variability. RESULTS Bodyweight, age, sex and CYP2C9 genotype significantly influenced S-warfarin clearance. The S-warfarin clearance was estimated to be 0.144 l h−1 (95% confidence interval 0.131, 0.157) in a 70 kg woman aged 69.8 years with the wild-type CYP2C9 genotype, and the volume of distribution was 16.6 l (95% confidence interval 13.5, 19.7). Bodyweight and age, along with the SNPs rs3814637 (in CYP2C19) and rs2242480 (in CYP3A4), significantly influenced R-warfarin clearance. The R-warfarin clearance was estimated to be 0.125 l h−1 (95% confidence interval 0.115, 0.135) in a 70 kg individual aged 69.8 years with the wild-type CYP2C19 and CYP3A4 genotypes, and the volume of distribution was 10.9 l (95% confidence interval 8.63, 13.2). CONCLUSIONS Our analysis, based on exposure rather than dose, provides quantitative estimates of the clinical and genetic factors impacting on the clearance of both the S- and R-enantiomers of warfarin, which can be used in developing improved dosing algorithms.
- Published
- 2011
41. A Semi-mechanistic Gastric Emptying Model for the Population Pharmacokinetic Analysis of Orally Administered Acetaminophen in Critically Ill Patients
- Author
-
George E. Dukes, Leon Aarons, Malcolm A. Young, Kayode Ogungbenro, Robert MacLaren, and Lakshmi S. Vasist
- Subjects
medicine.medical_specialty ,Time Factors ,Metoclopramide ,Critical Illness ,medicine.medical_treatment ,Population ,Prokinetic agent ,Administration, Oral ,Pharmaceutical Science ,Models, Biological ,Gastroenterology ,Enteral Nutrition ,Gastrointestinal Agents ,Pharmacokinetics ,Oral administration ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Antipyretic ,education ,Acetaminophen ,Pharmacology ,education.field_of_study ,Gastric emptying ,business.industry ,digestive, oral, and skin physiology ,Organic Chemistry ,Analgesics, Non-Narcotic ,digestive system diseases ,Erythromycin ,Parenteral nutrition ,Gastric Emptying ,Anesthesia ,Antiemetics ,Molecular Medicine ,business ,Algorithms ,Follow-Up Studies ,Biotechnology ,medicine.drug - Abstract
To develop a semi-mechanistic population pharmacokinetic model based on gastric emptying function for acetaminophen plasma concentration in critically ill patients tolerant and intolerant to enteral nutrition before and after prokinetic therapy.Acetaminophen plasma concentrations were available from a study with 10 tolerant and 20 intolerant patients before and after prokinetic therapy with either erythromycin or metoclopramide. Population pharmacokinetic modelling was carried out in a nonlinear mixed effects analysis software, NONMEM.A four-compartment semi-mechanistic model for stomach, intestine, central and peripheral compartments was described. The rate of emptying of the stomach was described by a first-order rate parameter. The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group. Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).The four-compartment semi-mechanistic population pharmacokinetic model adequately described the data. The gastric emptying half-time is improved by a factor of about 20 in the patients that are intolerant to enteral nutrition after treatment with prokinetic agents.
- Published
- 2010
42. Semi-mechanistic modelling approach to estimate rifampicin in vivo OATP ki using biomarker coproporphyrin 1 and rosuvastatin as probes
- Author
-
Karelle Ménochet, Kayode Ogungbenro, Hong Shen, Shelby Barnett, W. Griffith Humphreys, and Aleksandra Galetin
- Subjects
Pharmacology ,Chemistry ,In vivo ,medicine ,Cancer research ,Pharmaceutical Science ,Biomarker (medicine) ,Pharmacology (medical) ,Rosuvastatin ,Rifampicin ,medicine.drug - Published
- 2018
43. Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects
- Author
-
Ralph Woessner, Swati Dumitras, Leon Aarons, Thierry Wendling, Kayode Ogungbenro, and Etienne Pigeolet
- Subjects
Adult ,Male ,medicine.medical_specialty ,Food intake ,Indoles ,Adolescent ,Receptor, Metabotropic Glutamate 5 ,Pharmacology toxicology ,Pharmaceutical Science ,Administration, Oral ,Biological Availability ,Absorption (skin) ,Gastroenterology ,Models, Biological ,chemistry.chemical_compound ,Eating ,Young Adult ,Pharmacokinetics ,Internal medicine ,medicine ,Mavoglurant ,Humans ,Pharmacology (medical) ,Computer Simulation ,Pharmacology ,FOOD EFFECT ,business.industry ,Organic Chemistry ,Healthy subjects ,Middle Aged ,stomatognathic diseases ,chemistry ,Anesthesia ,Molecular Medicine ,Administration, Intravenous ,Female ,business ,Biotechnology - Abstract
To compare the pharmacokinetics of intravenous (IV), oral immediate-release (IR) and oral modified-release (MR) formulations of mavoglurant in healthy subjects, and to assess the food effect on the MR formulation's input characteristics.Plasma concentration-time data from two clinical studies in healthy volunteers were pooled and analysed using NONMEM®. Drug entry into the systemic circulation was modelled using a sum of inverse Gaussian (IG) functions as an input rate function, which was estimated specifically for each formulation and food state.Mavoglurant pharmacokinetics was best described by a two-compartment model with a sum of either two or three IG functions as input function. The mean absolute bioavailability from the MR formulation (0.387) was less than from the IR formulation (0.436). The MR formulation pharmacokinetics were significantly impacted by food: bioavailability was higher (0.508) and the input process was shorter (complete in approximately 36 versus 12 h for the fasted and fed states, respectively).Modelling and simulation of mavoglurant pharmacokinetics indicate that the MR formulation might provide a slightly lower steady-state concentration range with lower peaks (possibly better drug tolerance) than the IR formulation, and that the MR formulation's input properties strongly depend on the food conditions at drug administration.
- Published
- 2014
44. Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptying
- Author
-
Kayode Ogungbenro, Henry E. Pertinez, and Leon Aarons
- Subjects
Levodopa ,Time Factors ,Gastric emptying ,Chemistry ,Stomach ,Pharmacology toxicology ,digestive, oral, and skin physiology ,Pharmaceutical Science ,Pharmacology ,Models, Biological ,medicine.anatomical_structure ,Pharmacokinetics ,Gastric Emptying ,Plasma concentration ,medicine ,Humans ,Radionuclide imaging ,Effect compartment ,Radionuclide Imaging ,medicine.drug ,Acetaminophen ,Research Article - Abstract
Models have been developed to explain double-peaked plasma concentration-time profiles using mechanisms such as variable absorption and enterohepatic recirculation. Interruption of gastric emptying has also been shown to produce double-peaks, and this work proposes models for analysis of such data. In the presence of levodopa, gastric emptying is interrupted at times associated with double-peaks in pharmacokinetic profiles. Data from a simultaneous scintigraphy and paracetamol absorption study with levodopa was obtained, and models with compartments for stomach, intestine, central and peripheral tissue were developed to describe levodopa and paracetamol pharmacokinetics, including the double-peak phenomenon. The empirical model uses two gastric emptying parameter rates which are applied over separate time periods to describe the varying gastric emptying rate. The semi-mechanistic model uses a feedback mechanism acting via an effect compartment to link the plasma concentration of levodopa to the rate of gastric emptying, allowing levodopa pharmacokinetics to vary the rate of gastric emptying and give rise to a multiple-peaked plasma pharmacokinetic profile. The models were applied to plasma levodopa and paracetamol pharmacokinetic data with and without simultaneous analysis of scintigraphy data, in both cases giving a good fit and in the absence of scintigraphy data adequately predicting the stomach profile. For the semi-mechanistic model, the first-order constant governing gastric emptying was shown to switch between fast and slow values at a critical levodopa effect compartment concentration. New models have thus been proposed for analysis of plasma concentration profiles that exhibit double-peak phenomenon and applied successfully to levodopa data.
- Published
- 2014
45. A rational approach to dose optimisation of pembrolizumab and nivolumab using cost analysis and pharmacokinetic modelling and simulation
- Author
-
Robert Duncombe, Paul Lorigan, Kayode Ogungbenro, Alkesh Patel, and James Clark
- Subjects
0301 basic medicine ,Mathematical optimization ,Manchester Cancer Research Centre ,business.industry ,ResearchInstitutes_Networks_Beacons/mcrc ,Hematology ,Pembrolizumab ,Pharmacology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Pharmacokinetics ,030220 oncology & carcinogenesis ,Cost analysis ,Medicine ,Dose optimisation ,Nivolumab ,business - Published
- 2016
46. A rational approach to dose optimisation of pembrolizumab using cost analysis and pharmacokinetic modelling and simulation
- Author
-
Alkesh Patel, James Clark, Kayode Ogungbenro, and Paul Lorigan
- Subjects
Oncology ,Cancer Research ,education.field_of_study ,medicine.medical_specialty ,business.industry ,Population ,Pembrolizumab ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,030220 oncology & carcinogenesis ,Internal medicine ,Cost analysis ,Medicine ,Dose optimisation ,Every Three Weeks ,business ,education - Abstract
9547Background: Pembrolizumab is a PDL1 inhibitor licensed for the treatment of unresectable melanoma at a dose of 2mg/kg every three weeks. A population pharmacokinetic model based on two compartm...
- Published
- 2016
47. Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke
- Author
-
James Galea, Kayode Ogungbenro, Andrew D. Greenhalgh, and Nancy J. Rothwell
- Subjects
medicine.medical_specialty ,Phase iii trials ,Magnetic Resonance Spectroscopy ,Administration, Oral ,Pharmacology ,Toxicology ,Infusions, Subcutaneous ,Drug Delivery Systems ,Pharmacokinetics ,medicine ,Distribution (pharmacology) ,Humans ,Intensive care medicine ,Clinical scenario ,Stroke ,Administration, Intranasal ,Clinical Trials as Topic ,business.industry ,Endovascular Procedures ,Receptors, Interleukin-1 ,General Medicine ,medicine.disease ,Pharmacometrics ,Clinical trial ,Infusions, Intraventricular ,Neuroprotective Agents ,Drug development ,Blood-Brain Barrier ,Positron-Emission Tomography ,Drug Evaluation ,business - Abstract
INTRODUCTION: There is increasing recognition of the importance of translational pharmacokinetics in stroke research, lack of which has been cited as one of the main contributing factors to failure of Phase III trials. AREAS COVERED: The article reviews the translational issues in administration, distribution and sampling in the pharmacokinetics of putative therapeutic drugs in stroke. In addition, the role of translational pharmacometrics in drug development is discussed. The review uses the anti-inflammatory agent, IL-1 receptor antagonist, as an example. The reader will gain an insight into the pitfalls that are commonplace in translating pharmacokinetics from the preclinical to the clinical scenario. The reader will also gain an understanding of the complexities of blood-central nervous system (CNS) barriers in relation to brain pharmacokinetics and the increasing use of translational pharmacometrics in stroke research. EXPERT OPINION: The translation of preclinical to clinical pharmacokinetics is a discipline that is traditionally overlooked and is likely to be a key factor responsible for failure of clinical trials. With a clear comprehensive insight into the benefits and limitations of translational pharmacokinetics in stroke, translational pharmacokinetics can be safely used to enhance the efficacy of clinical trials in stroke and their likelihood of success.
- Published
- 2011
48. Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid
- Author
-
Leon Aarons and Kayode Ogungbenro
- Subjects
Pharmacology ,Breath test ,Carbon Isotopes ,medicine.diagnostic_test ,Gastric emptying ,Estimation theory ,Computer science ,digestive, oral, and skin physiology ,Gold standard (test) ,Models, Biological ,Intestinal absorption ,Pharmacokinetics ,Breath Tests ,Gastric Emptying ,Intestinal Absorption ,Control theory ,Gastric Mucosa ,medicine ,Identifiability ,Humans ,Tissue Distribution ,Identifiability analysis ,Caprylates ,Biological system ,Software - Abstract
Structural identifiability analysis is necessary for efficient parameter estimation and it is concerned with determination of whether the parameters in a model can be identified from specified experiments with perfect input-output data. Structural identifiability analysis is very important in mathematical modelling of biological and biomedical experiments and should be considered at the design stage of these experiments. There are three possible outcomes from a structural identifiability analysis; globally/uniquely identifiable, locally/non-uniquely identifiable or non-identifiable/unidentifiable. An ideal outcome is a globally/uniquely identifiable model, however a locally/non-uniquely identifiable outcome can help to identify areas of the model or experiment that need improvement. Despite the importance of structural identifiability analysis, it is still not widely used due to the heavy computational burden involved and the lack of software. A new software package, DAISY, that implemented differential algebra for identifiability analysis was recently released. DAISY is freely available, easy to use and does not require any high-level programming skill. The (13)C-octanoic acid breath test is now widely used for assessing the rate of gastric emptying in patients. Unlike scintigraphy, which is the gold standard and is a direct measure of the rate of gastric emptying, the (13)C-octanoic acid breath test is an indirect method for assessing the rate of gastric emptying. However the (13)C-octanoic acid breath test is cheaper, safer and easy to perform. Because the rate of excretion of (13)CO(2) in breath does not only reflect the rate of gastric emptying but other processes involved between the ingestion of (13)C-octanoic acid and elimination of (13)CO(2) in breath, the parameters commonly derived from the excretion data are not direct measures of gastric emptying. The aim of this paper was to propose a new semi-mechanistic model for the analysis of (13)C-octanoic acid breath excretion data and demonstrate the use of DAISY to assess the identifiability of the model. One- and two-compartment disposition models were linked to a model which has separate compartments for the stomach, intestine and breath. To obtain a globally identifiable model, a repeated (13)C-octanoic breath test in the same individual experimental design was also investigated and this adds a separate stomach compartment to the model. Finally the gastric emptying rate constant from the first (13)C-octanoic breath test was constrained to be the same as the absorption rate constant from the intestine. From the structural identifiability analysis carried out in DAISY, the model based on two experiments (baseline and treatment) and a constraint is globally identifiable. In summary, the present work describes a new semi-mechanistic model that will allow efficient and reliable assessment of the rate of gastric emptying from the (13)C-octanoic breath test.
- Published
- 2010
49. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study
- Author
-
Nancy J. Rothwell, Leon Aarons, Samantha Grainger, Peter J. Hutchinson, Andrew T. King, Stephen J. Hopkins, James Galea, Andrew D. Greenhalgh, Sylvia Scarth, Sharon Hulme, Pippa J. Tyrrell, and Kayode Ogungbenro
- Subjects
Adult ,Central Nervous System ,Male ,Subarachnoid hemorrhage ,subarachnoid hemorrhage ,Pilot Projects ,Cerebral Ventricles ,Central nervous system disease ,Cerebrospinal fluid ,Bolus (medicine) ,Pharmacokinetics ,medicine ,Humans ,interleukin-1 receptor antagonist ,Adverse effect ,Infusions, Intravenous ,Stroke ,Aged ,Dose-Response Relationship, Drug ,business.industry ,Middle Aged ,Dose-ranging study ,medicine.disease ,stroke ,cerebrovascular disease ,Interleukin 1 Receptor Antagonist Protein ,Neuroprotective Agents ,Neurology ,Nonlinear Dynamics ,Anesthesia ,Female ,Original Article ,neuroprotection ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine ,business ,pharmacokinetics ,Interleukin-1 - Abstract
The naturally occurring antagonist of interleukin-1, IL-1RA, is highly neuroprotective experimentally, shows few adverse effects, and inhibits the systemic acute phase response to stroke. A single regime pilot study showed slow penetration into cerebrospinal fluid (CSF) at experimentally therapeutic concentrations. Twenty-five patients with subarachnoid hemorrhage (SAH) and external ventricular drains were sequentially allocated to five administration regimes, using intravenous bolus doses of 100 to 500 mg and 4 hours intravenous infusions of IL-1RA ranging from 1 to 10 mg per kg per hour. Choice of regimes and timing of plasma and CSF sampling was informed by pharmacometric analysis of pilot study data. Data were analyzed using nonlinear mixed effects modeling. Plasma and CSF concentrations of IL-1RA in all regimes were within the predicted intervals. A 500-mg bolus followed by an intravenous infusion of IL-1RA at 10 mg per kg per hour achieved experimentally therapeutic CSF concentrations of IL-1RA within 45 minutes. Experimentally, neuroprotective CSF concentrations in patients with SAH can be safely achieved within a therapeutic time window. Pharmacokinetic analysis suggests that IL-1RA transport across the blood–CSF barrier in SAH is passive. Identification of the practicality of this delivery regime allows further studies of efficacy of IL-1RA in acute cerebrovascular disease.
- Published
- 2010
50. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results
- Author
-
Marylore Chenel, François Bouzom, Fanny Cazade, Kayode Ogungbenro, Leon Aarons, France Mentré, Institut de Recherches Internationales Servier (IRIS), Laboratoire Servier, Technologie Servier, Centre for Applied Pharmacokinetic Research (CAPR), University of Manchester [Manchester], School of Pharmacy and Pharmaceutical Sciences, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Comets, Emmanuelle, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)
- Subjects
Male ,Time Factors ,Computer science ,MESH: Drug Interactions ,Paired difference test ,Drug-drug interaction ,Analytical chemistry ,Wald test ,030226 pharmacology & pharmacy ,01 natural sciences ,Substrate Specificity ,010104 statistics & probability ,0302 clinical medicine ,Statistics ,Cytochrome P-450 CYP3A ,Drug Interactions ,Enzyme Inhibitors ,[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM] ,MESH: Cytochrome P-450 CYP3A ,education.field_of_study ,[SDV.BIBS] Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,Clinical Trials, Phase I as Topic ,MESH: Research Design ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,MESH: Predictive Value of Tests ,3. Good health ,Research Design ,MESH: Young Adult ,MESH: Enzyme Inhibitors ,medicine.drug ,Adult ,Physiologically based pharmacokinetic modelling ,Adolescent ,Midazolam ,Population ,Models, Biological ,Article ,03 medical and health sciences ,Young Adult ,MESH: Computer Simulation ,Predictive Value of Tests ,medicine ,Humans ,Computer Simulation ,0101 mathematics ,education ,Pharmacology ,MESH: Adolescent ,MESH: Humans ,MESH: Time Factors ,MESH: Models, Biological ,MESH: Adult ,MESH: Male ,NONMEM ,Standard error ,MESH: Clinical Trials, Phase I as Topic ,MESH: Midazolam ,Cytochrome P-450 CYP3A Inhibitors ,MESH: Substrate Specificity ,[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM] - Abstract
International audience; PURPOSE: To compare results of population PK analyses obtained with a full empirical design (FD) and an optimal sparse design (MD) in a Drug-Drug Interaction (DDI) study aiming to evaluate the potential CYP3A4 inhibitory effect of a drug in development, SX, on a reference substrate, midazolam (MDZ). Secondary aim was to evaluate the interaction of SX on MDZ in the in vivo study. Methods To compare designs, real data were analysed by population PK modelling technique using either FD or MD with NONMEM FOCEI for SX and with NONMEM FOCEI and MONOLIX SAEM for MDZ. When applicable a Wald test was performed to compare model parameter estimates, such as apparent clearance (CL/F), across designs. To conclude on the potential interaction of SX on MDZ PK, a Student paired test was applied to compare the individual PK parameters (i.e. log(AUC) and log(C(max))) obtained either by a non-compartmental approach (NCA) using FD or from empirical Bayes estimates (EBE) obtained after fitting the model separately on each treatment group using either FD or MD. RESULTS: For SX, whatever the design, CL/F was well estimated and no statistical differences were found between CL/F estimated values obtained with FD (CL/F = 8.2 l/h) and MD (CL/F = 8.2 l/h). For MDZ, only MONOLIX was able to estimate CL/F and to provide its standard error of estimation with MD. With MONOLIX, whatever the design and the administration setting, MDZ CL/F was well estimated and there were no statistical differences between CL/F estimated values obtained with FD (72 l/h and 40 l/h for MDZ alone and for MDZ with SX, respectively) and MD (77 l/h and 45 l/h for MDZ alone and for MDZ with SX, respectively). Whatever the approach, NCA or population PK modelling, and for the latter approach, whatever the design, MD or FD, comparison tests showed that there was a statistical difference (P < 0.0001) between individual MDZ log(AUC) obtained after MDZ administration alone and co-administered with SX. Regarding C(max), there was a statistical difference (P < 0.05) between individual MDZ log(C(max)) obtained under the 2 administration settings in all cases, except with the sparse design with MONOLIX. However, the effect on C(max) was small. Finally, SX was shown to be a moderate CYP3A4 inhibitor, which at therapeutic doses increased MDZ exposure by a factor of 2 in average and almost did not affect the C(max). CONCLUSION: The optimal sparse design enabled the estimation of CL/F of a CYP3A4 substrate and inhibitor when co-administered together and to show the interaction leading to the same conclusion as the full empirical design.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.